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ABSTRACT 
 
INTRODUCTION: Cervical cancer continues to be a significant cause of morbidity 
and mortality, particularly in women in the developing world, due to the lack of 
effective population screening. It has proven difficult to implement and sustain 
cytological screening programmes as health systems in these settings are not 
functional. South Africa has adopted an organised cervical screening programme, and 
the goal is to screen 70% of women over 30 years nationally, within ten years of 
initiating the programme.  However, it is also necessary to ensure that women with 
abnormal Pap smears are treated if we are to reduce cervical cancer incidence.  
Ensuring treatment of abnormal Pap smears is a challenge, and current data on this is 
needed to inform service delivery. 
 
AIM: The study aims to assess the current status of the cervical screening programme 
in the Johannesburg Metro District, specifically looking at screening coverage, and 
referral for treatment in women with abnormal Pap smears. 
 
METHODOLOGY: Secondary analysis of data in the District Health Information 
System was done; and registers at a sample of primary health care clinics and their 
referral colposcopy services were evaluated for the period April 2007 – March 2008. 
Descriptive statistics were employed to analyse the data. Multivariate analysis was 
also done to evaluate factors associated with colposcopy attendance. 
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RESULTS: Screening coverage for the district was 6.3% for 2008 and the cumulative 
coverage from 2000 to 2008 was 35.8%, with significant variation between sub-
districts. A high proportion (19%) of smears was done in women less than 30 years.  
 
Of 557 women with abnormal Pap smears requiring further treatment, 57% were 
informed of their results and referred, 38% had appointments for colposcopy, and 
only 28% attended these appointments.  Women experienced long waiting times for 
appointments (up to 15 months), and there was inadequate record keeping and client 
tracing. HIV status and the sub-district and health authority where women were 
screened were associated with colposcopy attendance; the referral hospital was 
associated with length of waiting time between Pap smear and colposcopy. 
 
CONCLUSION: Cervical screening coverage is below target, and the referral for 
diagnosis and treatment remains a challenge.  Unless referral and access to 
colposcopy services is improved, increasing screening coverage will not have an 
impact on decreasing cervical cancer incidence and mortality. It is hoped that this 
study will provide the data to target interventions to improve cervical screening 
coverage and effective referral and treatment in the district. 
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GLOSSARY 
 
Coverage: The proportion of women in the target age group who are screened at the 
recommended intervals during a given time period.  
 
Cervical Intraepithelial Neoplasia (CIN): A precancerous condition involving the 
covering layer (epithelium) of the cervix. The condition is graded as CIN 1, 2 or 3, 
according to the thickness of the abnormal epithelium (1/3, 2/3 or the entire thickness) 
 
High-grade lesion: A term used in the Bethesda classification to denote cervical 
abnormalities that have a high likelihood of progressing to cancer if not treated. 
Includes CIN 2 and CIN 3 
 
Screen-negative: Result of a screening procedure that shows no abnormality. 
 
Screen-positive: Result of a screening procedure that shows an abnormality 
 
Squamous intraepithelial lesion (SIL): Pre-cancer or abnormality of the squamous 
cells of the lining of the cervix. The Bethesda classification distinguishes between 
low-grade SIL (LSIL) and high-grade SIL (HSIL).  
 
Referral: Physical referral of women to a clinical facility as a consequence of the 
screening test for diagnostic confirmation, e.g. by histology. 
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Screen and treat: A procedure where testing, confirmation and treatment take place 
during the same episode. 
 
Screening interval: Fixed interval between routine screenings decided upon in each 
programme, depending on screening policy. 
 
Screening policy: Specific policy of a screening programme which dictates the 
targeted age group, the geographical area, the screening interval, etc. Opportunistic 
systems may also have policies. 
 
Target population: The population eligible for screening, i.e. all women 
recommended undergoing screening according to the policy adopted. 
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ABBREVIATIONS AND ACRONYMS 
 
AGUS atypical glandular cells of unknown significance 
AIDS acquired immunodeficiency syndrome 
ART antiretroviral therapy 
ASC-H atypical squamous cells: cannot exclude a high-grade squamous intra-
epithelial lesion 
ASC-US atypical squamous cells of undetermined significance 
ASR age-standardised incidence rate  
CHBH Chris Hani Baragwanath Hospital 
CHC community health centre 
CHW community health worker 
CIN cervical intraepithelial neoplasia 
CMJAH Charlotte Maxeke Johannesburg Academic Hospital 
DHIS District Health Information System 
EH Edenvale Hospital 
HGL high grade lesions 
HIV human immunodeficiency virus 
HPV human papillomavirus 
HSIL high-grade squamous intraepithelial lesion 
IARC International Agency for Cancer Research 
JMD Johannesburg Metro District 
LBC Liquid-based cytology 
LG local government 
LSIL low-grade squamous intraepithelial lesion 
  
xv 
NCR National Cancer Registry 
NGO non-governmental organisations 
NHLS National Health Laboratory Service 
PHC primary health care 
RMH Raheema Moosa Hospital 
SIL squamous intraepithelial lesion 
Stats SA Statistics South Africa 
VIA visual inspection with acetic acid 
VILI visual inspection with Lugol’s iodine 
WHO World Health Organization 
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CHAPTER ONE 
1. INTRODUCTION 
 
1.1 Background 
Cervical cancer continues to be a cause of significant morbidity and mortality in 
women, particularly in the developing world.1 Globally, it is the second most 
commonly diagnosed cancer and is the third leading cause of cancer deaths in 
women.2 In South Africa, it remains one of the top two most commonly reported 
cancers in females, comprising 16.2% of all cancers in this group.3 Cervical cancer is 
an even greater concern in South Africa due to the high prevalence of Human 
Immunodeficiency Virus (HIV) and Acquired Immune Deficiency Syndrome (AIDS), 
with which it is known to be associated.4  
 
Without urgent action, deaths due to cervical cancer are projected to rise by almost 
25% over the next 10 years.5 These deaths could be prevented if the disease is 
detected early. The slow progression from mild dysplasia to carcinoma makes cervical 
cancer a feasibly preventable disease and provides the rationale for screening. There 
are various methods of screening but cytology is recommended for large-scale 
cervical cancer screening programmes, where sufficient resources exist.1  
 
Screening for cervical cancer by means of Papanicolaou (Pap) smear became part of 
the package of care offered free of charge to all women in South Africa in 1996, and 
in 2001, a national cervical screening programme was launched.6 According to the 
national policy, every asymptomatic woman aged 30 years or older will be screened 
three times in succession at ten year intervals, utilising cervical Pap smears.6 The 
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objectives of the programme, as expressed in the national guidelines, are to reduce the 
incidence, morbidity and mortality associated with cervical cancer; and to ultimately 
reduce the excessive expenditure of scarce health funds currently spent on the 
treatment of invasive cancer of the cervix.6 
 
 
1.2 Statement of the Problem 
In many developing countries where the burden of disease is highest, access to health 
services is limited and screening for cervical cancer either does not exist or does not 
reach the majority of women who need it.5 It has proven difficult to implement and 
sustain effective population screening programmes in low-resource settings.7 South 
Africa has a cytological screening programme in place but many challenges exist in 
implementing the screening programme.8-10 A lack of political will, adequate financial 
resources and trained staff, effective referral mechanisms and laboratory facilities, and 
a health care infrastructure for diagnosis and treatment, along with many competing 
healthcare priorities, have hampered the organisation of effective cytological 
screening programmes in resource-poor countries, including South Africa.11 
 
A successful cervical cancer control programme requires a high coverage rate above 
80%, but this has not been achieved in South Africa.9 Also, women with identified 
abnormalities should attend for diagnosis, management and follow-up but studies 
have shown that many women who have precancerous or cancerous lesions on Pap 
smears are often not referred to colposcopy services for diagnosis and treatment.8,12,13  
If women with abnormal smears are not referred and treated, all attempts to increase 
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coverage would be ineffective in decreasing the incidence and mortality of invasive 
cervical cancer, which is the ultimate goal of the programme.  
 
This study aims to evaluate the cervical screening programme in the Johannesburg 
Metro District (JMD), a densely-concentrated urban metropolis in the Gauteng 
Province.  An evaluation of the programme will be done using a health services 
research and evaluation approach. This will evaluate progress thus far regarding 
screening coverage and other programme output indicators. The study will also 
evaluate referral and treatment services to determine the programme’s effectiveness 
and performance in referral of women with high-grade lesions. 
 
 
1.3 Justification for the Study 
The South African national cervical screening programme is approaching the ten year 
mark since its inception in 2000. This is a milestone because a goal of the programme 
was to have screened 70% of the target population by 2010.6 It is therefore important 
to evaluate the programme at this point in order to measure the progress attained 
towards reaching those goals.  
 
The World Health Organization (WHO) recommends that middle-income developing 
countries with inefficient cytology screening programmes should focus their attention 
on reorganising their programmes considering lessons from their past failures and 
experiences from elsewhere.5 Many local studies have documented challenges 
experienced in different aspects of the screening service, and the resulting impacts on 
screening coverage, quality of Pap smears and effectiveness of referral 
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mechanisms.8,13,14 However, there has not been a systematic evaluation of the South 
African national cervical screening programme, and evidence especially at district 
level of output indicators for the current screening programme is limited.  
 
In order to reorganise the screening programme at district level, it is important to 
understand the specific challenges and barriers to successful implementation 
screening in the local context. Therefore, good data from Johannesburg Metro District 
and the Gauteng Province is necessary in order to inform improvements to the 
programme in this setting. This study hopes to provide much-needed information for 
district and provincial managers to inform further recommendations to improve 
cervical screening coverage and effective referral and treatment in the district. 
 
 
1.4 Literature Review 
 
1.4.1. Burden of disease 
Despite being highly preventable and curable, cancer of the cervix remains a 
significant health problem, particularly in developing countries.1,14  One in ten cancers 
reported worldwide are cancers of the cervix, and it remains the most commonly 
diagnosed female cancer in sub-Saharan Africa, South and Central America and south 
and south-east Asia.15,16  Globally, over 85% of the nearly 560 000 new cases and the 
309 000 deaths annually, occur in the developing world.2  While incidence is 
declining in most developed and some developing countries due to effective screening 
programmes, the total burden of cervical cancer is rising in high-risk developing 
countries in sub-Saharan Africa. There is a seven-fold variation in incidence and 
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seventeen-fold variation in mortality from cervical cancer between developed and 
developing regions of the world.1   
 
Cervical cancer is a relatively common disease in South Africa.17 According to 
National Cancer Registry (NCR) reports, cervical cancer consistently remains one of 
the top two most common cancers in South African women.3,18 A total of 4 817 
cervical cancer cases were reported to the NCR in 2001, comprising 16.2% of all 
cancer cases reported in females in that year.3 The age-standardised incidence rate 
(ASR) of cervical cancer was 26 per 100 000 women. ASR increased with increasing 
age, with 81% of cases occurring in women between 30 and 69 years, and incidence 
peaking between the ages of 60 and 64 years. ASR in White females was significantly 
lower (32 per 100 000) than in Black females (122 per 100 000).  There is a 
disproportionate burden of the disease in Black women, who have a 1 in 29 lifetime 
risk of developing the disease, probably reflecting the differential exposure to risk 
factors and access to health screening services. 
 
1.4.2. Natural history of disease and risk factors 
Invasive cervical cancer develops from dysplastic precursor lesions, progressing 
steadily from low-grade to high-grade lesions, and finally to cancer.5  
 
The primary underlying cause of cervical cancer is infection with high-risk human 
papillomavirus (HPV) types.19 Most HPV infections resolve spontaneously; those that 
persist may lead to the development of pre-cancer and cancer. It usually takes 10 to 20 
years for precursor lesions caused by HPV to develop into invasive cancer.  
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The key determinants of HPV infection for both men and women are related to sexual 
behaviour including early onset of sexual activity, multiple sexual partners and 
unprotected intercourse.5 Additional co-factors are active and passive exposure to 
cigarette smoke, long use of oral and injectable contraceptives and 
immunosuppression.5,20 
 
HIV and cervical cancer 
Cervical cancer was classified an AIDS-defining disease in 1993,21 and it has since 
been observed to be the most common AIDS-related cancer in women in Africa.22 
Studies have shown that HIV positive women have a higher prevalence of HPV 
infection with multiple high-risk HPV types, and are at a greater risk of developing 
cervical squamous intraepithelial lesions (SIL) and cervical cancer.23-25  Several 
studies have reported the prevalence of SILs in HIV positive women to be 31% to 
63%.24,25  Evidence has shown that cervical lesions in HIV positive women tend to 
appear up to ten years earlier than in HIV negative women, progress more rapidly and 
are associated with higher mortality.5,26  An increase in pre-cancerous cervical lesions 
with increasing HIV prevalence has been documented in many settings, including 
South Africa.27  A case-control study of cancers in Johannesburg hospitals from 1995-
2004, showed HIV positive women had 1.6 times higher risk of developing cervical 
cancer than HIV negative women.28  A strong association between immune status 
(CD4 and viral load) and cervical abnormalities has been demonstrated.29-31 
 
South Africa has the largest, expanding HIV burden in the world.  It is estimated that 
5.7 million South Africans are currently living with HIV/AIDS, 60% of them 
women.32 In 2008, the adult prevalence in the age group 15-49 years was estimated at 
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16.9% 33 while the latest antenatal seroprevalence was 28%.34 Considering the high 
prevalence of HIV especially in young women and the association with cervical 
cancer, the potential impact on disease burden deserves even greater scrutiny.  The 
absence of an increased trend in cervical cancer incidence in recent years 3 is 
attributed to high competing mortality and deaths from other causes.35  Increasing 
access to antiretroviral therapy (ART), however, may result in increasing life 
expectancy, which in turn may lead to a higher cumulative risk of developing cervical 
cancer.25 Some have argued for a possible re-examination of criteria being used for 
cervical cancer screening in high HIV prevalence countries where the prevalence of 
cervical cancer is also high and access to antiretroviral treatment remains limited.27 
 
1.4.3. Cervical cancer prevention 
Cervical cancer is highly preventable either through primary prevention of exposure 
to risk factors, or through secondary prevention which is early detection and treatment 
of precancerous lesions through cervical screening. 
 
Primary prevention involves prevention of HPV infection and cofactors known to 
increase the risk of cervical cancer, and includes education and awareness-raising to 
reduce high-risk sexual behaviours; provision of the HPV vaccine; and efforts to 
discourage tobacco use, including smoking.5  
 
There is currently no available evidence on the effectiveness of behaviour change 
intervention, such as advising abstinence, delaying first intercourse, having fewer 
sexual partners, and using condoms, in reducing cervical cancer disease burden. 
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HPV vaccines: Recently developed candidate HPV vaccines designed to protect 
against infections with high risk HPV 16 and HPV 18 have shown promising results 
in clinical trials.5 However, there are some programmatic concerns that still need to be 
addressed particularly in developing countries for these vaccines to be effective at 
population-level. For example, the vaccine should be equitably distributed in order to 
attain high coverage of adolescents before they become sexually active.5 Also, 
acceptable coverage of young people is best achieved through a functional school-
based public health system, which is not yet well established in South Africa.9 Any 
impact of the vaccine on the incidence of cervical cancer would not be detectable for 
some decades after its introduction. Even after an HPV vaccine programme is fully 
implemented, there would still be a need for widespread cervical screening to 
continue.4,5 
 
Secondary prevention stops the progression of pre-cancerous disease once it has 
already started. The natural history of cervical cancer, with its usually slow 
progression from early pre-cancer to invasive disease, provides the rationale for 
screening.5 The objective of cervical screening is to prevent invasive cervical cancer 
by detecting and treating women with cervical cancer precursor lesions. Screening 
tests such as cervical cytology, visual tests, and HPV testing may all be used to 
identify precursor lesions. Regardless of the test used, the key to an effective 
programme is to reach the largest proportion of women at risk with quality screening 
and treatment of precursor lesions.5  
 
Cytological screening: Cytological testing involves collection of exfoliated cells from 
the cervix using a spatula or brush, and microscopic examination of these cells after 
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staining. In South Africa, women with low-grade lesions are generally advised to 
return for routine follow-up smears. Women with high-grade precursor lesions are 
further evaluated via colposcopy, biopsy, and subsequent treatment of confirmed 
lesions. 
 
Cytological screening requires a laboratory infrastructure; trained cytotechnologists 
and pathologists for processing slides and reporting; internal and external quality 
control; and a system for communicating the results to the women. It is also necessary 
for all women with high grade lesions on Pap smear to be referred for colposcopic 
diagnosis and management. The notification of results to women, as well as the three 
visits (one each for testing, diagnosis, and treatment) required for cytological 
screening, pose major programmatic and logistic challenges.11 Despite this, the Pap 
smear is the only test that has been used in large populations and that has been shown 
to reduce cervical cancer incidence and mortality.4,5 It is therefore still the 
recommended method of choice for cervical screening. 
  
Liquid-based cytology (LBC): LBC is more expensive than conventional cytology 
and laboratory staff needs to be specially trained.5 However, it appears to have a 
number of advantages over conventional methods: there are fewer false negatives; 
fewer unsatisfactory specimens; each specimen requires a shorter interpretation time; 
and the material collected can also be tested for HPV DNA.5 The high cost however, 
makes it suitable for use only in settings where resources permit. 
 
Visual methods: Two visual methods are available, viz. visual inspection with acetic 
acid (VIA) and visual inspection with Lugol’s iodine (VILI). VIA and VILI are 
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promising alternatives to cytology where resources are limited because they do not 
rely on laboratory services, require a very low level of infrastructure, can be 
performed by a wide range of health personnel after a short period of training (1–3 
weeks), are inexpensive, safe and acceptable techniques, and results are available 
immediately, eliminating the need for multiple visits in most cases, thus reducing loss 
to follow-up.5  
 
However, high rates of overtreatment may result, given their relatively low test 
specificity. Visual inspection methods are subjective and present challenges to 
maintain the quality of testing. There is also no permanent record of the test that can 
be reviewed later. Therefore, visual screening methods, at this time, are recommended 
for use only in pilot projects or other closely monitored settings.4,5  
 
HPV DNA-based screening methods: The HPV DNA test is simple to perform and 
has an increased screening sensitivity when combined with cytology, but requires a 
second clinic visit and costly laboratory infrastructure, making it unaffordable for low 
resource settings.4,5 Detection of high-risk HPV does not necessarily mean that pre-
cancer or cancer is present; it indicates simply that there is an HPV infection. Using 
HPV testing for screening would lead to a large proportion of women being told that 
they harbour a sexually transmitted viral infection that can ultimately cause cancer.5 
HPV DNA tests as primary screening methods, at this time, are recommended for use 
only in pilot projects or other closely monitored settings.4,5 They can be used in 
conjunction with cytology or other screening tests, where sufficient resources exist. 
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The “screen-and-treat” approach: If there is no capacity for colposcopy services, 
treatment based on screening alone may be appropriate, especially in limited-resource 
settings. Screening tests for the screen-and-treat approach can include visual tests, 
HPV or cytological tests. With screening tests that provide immediate results, such as 
VIA and VILI, screening and treatment can be provided during a single hospital visit, 
thus reducing the screening programme’s susceptibility to loss to follow-up.5,36  In 
recent South African studies, one-visit strategies with visual inspection methods were 
demonstrated to be safe, more cost-effective, requiring only one visit, and were able 
to be performed by mid-level nurses in primary care settings, but would result in some 
overtreatment.37,38  However, they had a lower specificity and positive predictive 
value, and are associated with over-referral to colposcopy and significant 
overtreatment.39  Until these methods are proven in settings other than experimental 
ones, cytological screening remains the standard for application in low- and middle-
income countries, and the alternative screening tests are still seen as complementary 
to cytology rather than competitive.40   
 
1.4.4. Cytological cervical screening programmes 
Much experience and evidence-based knowledge is available on the use of cytological 
screening in both developed and developing countries.4,5 High quality cytology is a 
highly specific screening test, with estimates of the order of 98-99% and moderate 
sensitivity as high as 75%.5 Well-organised cervical cytological screening 
programmes, involving screening of sexually active women annually or every 2-5 
years, have been effective in reducing the incidence of and mortality from the disease 
in developed countries in the last 40-50 years.5,41 In areas with high-quality screening, 
high coverage, and reliable follow-up of women, cytological screening has reduced 
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cervical cancer rates by 60% to 90% within three years of introduction to populations 
that had not previously been screened.5,7  Even in countries where screening 
programmes are not ideally functioning, population-based screening programmes- 
either organised or opportunistic- have decreased the incidence of and mortality from 
cervical cancer in large parts of the world.42,43  In South Africa, a study has shown 
that even limited Pap smear screening reduced the risk of cervical cancer.44  
 
An analysis of trends in cervical mortality in South Africa from 1949 to 1990 revealed 
a consistent decline in deaths in White women from the 1960s after screening was 
introduced, while increased mortality was recorded in Coloured women.45  This 
provides circumstantial evidence that screening had an impact on cervical cancer 
mortality in White women, while the increase in mortality seen in the Coloured 
population in that time reflects the inequitable distribution of and access to these 
services. 
 
The high incidence and mortality of the disease in developing countries has been 
attributed to the lack of effective cervical screening programmes.  The limited health 
care budgets in these settings do not allow initiation and sustaining of comprehensive 
programmes that involve substantial costs for the associated infrastructure, 
manpower, consumables, follow-up, and surveillance.7 Other reasons why screening 
has not been implemented in developing countries include: 
 lack of priority for women’s sexual and reproductive health 
 lack of national policies and appropriate guidelines  
 lack of awareness of cervical cancer among the population, health care 
providers and policy-makers 
  
13 
 limited access to health care services 
 lack of functional referral systems 
 
In resource-poor settings, the WHO supports the concept of achieving wider coverage 
rather than more frequent screening.5 This is because increasing coverage has the 
potential to reduce disease incidence far more than using a slightly more sensitive 
screening test or decreasing screening intervals.46 The WHO advises that countries 
should focus on screening women between the ages of 30 and 49 years at least once in 
their lifetime, gradually expanding the programme to other age groups and then to 
more frequent screening.  The WHO further recommends that existing organised 
programmes should not include women less than 25 years of age in their target 
populations as there is minimal benefit and substantial harm in screening below age 
25; and screening is not recommended for women over 65 years, provided the last two 
previous smears were negative. Annual screening is not recommended at any age by 
WHO.5 Many national programmes are moving towards decreasing the frequency of 
smears (once every 3-5 years) due to the slowly progressing nature of these lesions.7  
 
Organised cytological screening is designed to reach the highest possible number of 
women at greatest risk of cervical cancer. It is usually planned at the national or 
regional level. Opportunistic screening is screening done independently of an 
organised or population-based programme, on women who are visiting health services 
for other reasons. This form of screening tends to reach younger women at lower risk, 
who are attending antenatal, child health and family planning services. Organised 
screening programmes designed and managed at the central level are preferable to 
opportunistic screening, as they are more cost-effective, and make better use of 
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available resources while ensuring that the greatest number of women will benefit. 
However, both organised and opportunistic screening can fail because of poor quality-
control, low coverage of the population at risk, over-screening of low-risk 
populations, and high loss to follow-up.  
 
Success of a population based cytological cervical screening programme is dependent 
on a number of critical factors:47 
 Client recruitment: creating demand for screening services by educating 
communities and recruiting women in health facilities 
 Screening service: providing screening services and ensuring high coverage 
(80%) of the population at risk; and good Pap smear quality 
 Cytology service: standardising laboratory-based screening and reporting, 
while minimising turn-around times 
 Client management at primary care level: establishing mechanisms for 
informing clients of results and for tracking clients who need recall for re-
screening or referral for further management 
 Colposcopy and treatment services: ensuring women’s access to these 
services, by establishing mechanisms for referral to and feedback from 
services providing treatment for pre-cancerous lesions 
 Monitoring and evaluation: ensuring mechanisms are in place to collect and 
analyse key cervical screening data for monitoring and evaluating the 
screening programme 
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Cytology-based screening programmes have proven difficult to implement and sustain 
in low-resource settings, because of the above-listed inherent requirements of a 
cytology-based programme. These include highly trained personnel, well-equipped 
laboratories, transport of specimens, and an effective system for collecting 
information and following up patients. High quality laboratories and colposcopy 
services for diagnosis and treatment are often not consistently available and accessible 
in these settings.37 In addition, the demands of other competing health needs often 
result in a lack of resources or political will to make cervical cancer screening a 
priority.  
 
Although cytological screening is being carried out in some developing countries, 
there are no organised programmes and the testing is often of poor quality and 
performed inadequately and inefficiently among the population. As a result, there has 
been a very limited impact on the incidence of cervical cancer.7 Cervical screening 
has been offered in Chile, Colombia, Costa Rica, Cuba and Mexico since the 1970s 
but this has not resulted in declines in disease and deaths, despite some settings 
attaining high coverage rates above 80%. Coverage has been variable across regions, 
with rural areas being particularly underserved. In addition, there have been no 
systematic efforts at call, recall and follow-up of screened women.7 Other countries 
with opportunistic screening efforts like Brazil and Peru continue to demonstrate high 
rates of cervical cancer incidence and mortality, and even in Singapore where high 
levels of opportunistic screening are conducted, impact has been minimal.7  
 
In sub-Saharan Africa, where the burden of disease is perhaps greatest, no organised 
or opportunistic screening programmes exist apart from South Africa.7 It is essential 
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to provide cervical cancer screening services in sub-Saharan Africa as this region 
carries a high burden of disease.11 Most of the least functional health-care delivery 
systems are in Africa. The challenge for Africa is to develop screening services 
integrated into existing health services in such a way as to improve the overall 
functioning of health-care systems.4 Many countries are currently investigating the 
feasibility of visual methods as an alternative to cytological screening. 
 
In light of the difficulties in implementing a cervical cytological screening 
programme in low-resource settings, more attention is now being paid to other 
methods of screening, especially those requiring single visits.  Proponents of 
cytological screening methods still advocate that any failures are not attributable to 
inadequacies of the Pap smear test, but relate more to lack of political will and poor 
programmatic management, to which all screening methods are vulnerable.48,49 The 
cytology test has been shown to be effective when well applied. Where cytology 
screening has failed to work, blame can be laid on the design or delivery of the 
screening service.4 Choosing a suitable screening test is only one aspect of a screening 
programme. A more fundamental and challenging issue is how the programme is 
organised and implemented. 
 
Screening programmes often focus on cytology services, but women who are found to 
have abnormalities on screening need follow-up, diagnosis and possibly treatment, in 
order to prevent the development of cancer or to treat cancer at an early stage. Efforts 
to increase coverage will be wasted if those who test positive are not followed up 
correctly. This requires effective links between programme components (e.g. from 
screening to diagnosis and treatment). Organised programmes with systematic call, 
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recall, follow-up and surveillance systems have shown the greatest effect (e.g. in 
Finland and Iceland), and also used fewer resources than unorganised programmes 
(e.g. in the USA).7 
 
1.4.5. Cervical screening programme implementation in South Africa 
South Africa launched a national cytology-based cervical cancer control programme 
in 2001, which involves provision of three free Pap smears for women over 30 years 
at ten year intervals.6 It is projected that this will result in a 64% reduction in 
cumulative incidence of cervical cancer.50 The ultimate goal of the policy is to screen 
at least 70% of women, nationally, in the target age group within ten years of 
initiating the programme.6 
 
The national cervical screening guideline gives very little detail about implementation 
of the programme, but does inform the process of follow-up based on the Pap smear 
result.6 The guideline also defines referral criteria to colposcopy services. It addresses 
the issue of recalling clients to inform them of their results within one to four weeks 
of having a Pap smear, with the responsibility to trace patients who have not returned 
for their results resting with the provider institution.  Patients who miss colposcopy 
appointments should also be traced by the screening institution. In terms of quality 
control, the guideline requires the laboratory service to inform clinics of their 
adequacy rates, with retraining being instituted if this drops below 70%.6 
 
In accordance with the principles of the district health system, the organisation of the 
programme is decentralised, with Pap smears provided at no cost at every primary 
health care facility as well as hospitals. Colposcopy services are supposed to be 
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provided at referral hospitals. The National Department of Health retains 
responsibility for policy, guidelines, education materials, coordination and budgeting. 
The district and local government health departments are tasked with delivering the 
programme. 
 
Challenges in programme implementation in South Africa 
Despite the policy framework that exists in South Africa, progress in cervical cancer 
screening has been slow and hard to achieve.4 As in other settings, local studies have 
shown that barriers to an effective cervical screening programme exist both at 
community and health service level.7 Lack of resources and available treatment 
services, low community awareness, poor quality of Pap smears, and inadequate rates 
of follow-up are foremost among the challenges documented.8,9 
 
a. Health system capacity 
The national cervical screening programme is not functioning effectively due to the 
underlying systemic problems with the South African health system.9,10 It is due in 
part to the demands on the health system of competing health needs, such as HIV, 
tuberculosis and maternal mortality. Other constraints include lack of funding, 
infrastructure and human resources required to sustain screening programmes.9 Task 
shifting has seen a change to nurse-led provision of Pap smears, but human resource 
challenges still exist.10 The South African public health system is faced with an acute 
shortage of healthcare workers that function with extremely high workloads. In 
addition, inadequate attention has been paid to nurses’ knowledge, skills and attitudes 
with regard to cervical screening.10 Studies have shown that not enough nurses are 
trained to provide Pap smears51, and nurses report reluctance to take on Pap smear 
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provision due to fear of increasing their workload.13,51 In recent years, facilities and 
infrastructure have been greatly improved without visible improvements in the 
screening programme. For example, in the Free State, the numbers of cytology 
laboratories, colposcopy clinics and the distribution of primary health care facilities 
have improved, yet the proportion of women receiving Pap smears decreased by 
almost 50% reportedly due to increased workloads in primary health clinics post-
1994.14  
 
A functioning health system is necessary to coordinate the many aspects of a 
cytological screening programme.10 Some argue that South Africa has not invested 
sufficiently in health system strengthening or in building the management capacity to 
implement an effective screening programme.8  
 
b. Population awareness 
Cervical screening coverage remains suboptimal in South Africa, due in part to poor 
public awareness which results in low participation in the screening programme. A 
nation-wide population-based study of over 20 000 women over 25 years revealed 
that 80% of women had never had a Pap smear.17 A study from a rural area of South 
Africa indicated that 64% of 538 women attending primary health care clinics had 
ever heard of Pap smears and only 56% of these women had ever had a Pap smear.52 
Project Screen Soweto aimed to set up a cervical screening programme in Soweto in 
the early 1990s, but was terminated after five years due to poor performance. This 
was attributed largely to a lack of planned population awareness which resulted in 
poor participation.53 
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c. Screening coverage 
Screening statistics at a national level are not readily available, and when they are 
available for specific provinces, they often show poor coverage. A review of the 
implementation of the cervical screening programme in South Africa suggested that 
even recent increases in screening have still fallen short of targets. The author also 
commented further that relatively large numbers of women in South Africa remain 
unscreened.9 Worryingly, in some settings coverage appears to be declining. For 
example, in the Free State province in 2002, 4.1% of the studied population was 
screened, compared with 7.1% in 1985.14 
 
d. Target age group 
Screening continues to be performed in young women who are not in the defined 
target age groups for the South African screening programme. A multicentre study 
showed 16-30% smears were done on women less than 30 years;8 a study in the 
Western Cape reported that 84% of Pap smears were done in women less than 30 
years;13 and another study set in the Free State province found 65% of smears to be 
performed in women under 35 years.54 This is partly because screening has been done 
opportunistically (on younger women) as part of family planning or postnatal visits. 
Much of this is related to staff knowledge, attitudes and practices regarding cervical 
screening.13 
 
e. Screening in HIV positive women 
The National Guidelines on Cervical Screening makes no specific recommendations 
on screening age and frequency for HIV positive women.6 Although no published 
data is available on cervical screening in HIV positive women outside of research 
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settings, there are anecdotal reports that the high proportion of smears done on women 
under 30 years in recent years probably reflects the smears done on HIV positive 
women.55 Cervical smears are performed in this group for pre-screening before 
commencing ART and thereafter annually, in line with a current HIV/AIDS 
management protocols for HIV-positive women who are immune compromised (CD4 
< 350).9 Performing smears on HIV positive women who fall outside the screening 
programme target population may divert attention and resources from, and therefore 
undermine the screening programme.  
 
f. Pap adequacy 
Data regarding the adequacy of Pap smears are unavailable but are necessary for 
quality assurance.10 In one study in the Western Cape, only 56% of the smears taken 
were considered adequate for evaluation by the laboratory, with nearly half of 
reviewed samples lacking a sufficient component of endocervical cells.13 Poor Pap 
smear adequacy is especially a problem as it results in a significant waste of resources 
and missed opportunities for effective screening. 
 
g. Referral and treatment 
In many programmes in middle-income countries50 and even developed countries56, 
women with an abnormality on Pap smear commonly fail to return to the clinic for 
management.  South African studies suggest that up to 50% of women with HSIL Pap 
smear results do not access a colposcopy clinic for diagnosis and treatment.51,57,58 The 
loss to follow-up is blamed on multiple health facility visits that are required in a 
cytological screening programme, the limited capacity to track women who do not 
return for Pap results or colposcopy appointments, and poor referral systems.11,51 An 
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economic evaluation of different screening methods in South Africa identified failure 
to attend for investigation and treatment of abnormalities as a major factor in reducing 
the cost–effectiveness of cytology.38 Without adequate referral and treatment of 
women with precancerous lesions, any increases in screening coverage rates will fail 
to decrease cervical cancer incidence and mortality. 
 
h. Health Information Systems 
Establishing well-functioning information systems are essential for successful 
monitoring and evaluation of a cervical screening programme.7,59 The District Health 
Information System (DHIS) in South Africa reports on only two cervical screening 
indicators, viz. screening coverage and smear abnormality rate.60  The DHIS does not 
report on other process indicators, including screening of women outside target age 
groups, smear adequacy, smear abnormality, colposcopy referral and attendance, and 
HSIL treatment rates, which are pivotal in order to inform how well the programme is 
doing.  For example, it is not known what percentage of all women with abnormalities 
screened in the last year in Johannesburg or Gauteng has been treated to prevent 
cervical cancer. 
 
In conclusion, cervical cancer is a well recognised health problem in South Africa 
owing in some part to gaps in the implementation of the national cervical screening 
programme. Hence this research project was done to evaluate the programme in the 
district in order to identify key areas for improvement. 
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1.5 Purpose of the Study 
 
1.5.1 Aims of the Study 
The overall aim of the project is to evaluate the cervical screening programme in the 
Johannesburg Metro District, Gauteng Province, looking specifically at screening 
coverage, and referral for treatment of precancerous lesions. 
 
1.5.2 Objectives of the Study 
1. To determine and analyse process indicators used for monitoring the cervical 
screening programme in Gauteng, including: 
a. Cervical screening coverage  
b. The proportion of smears done for the target age group 
c. Smear abnormality rate 
d. Smear adequacy rate 
 
2. To assess the availability and use of referral services for diagnosis and management 
of pre-cancerous lesions, including:  
a. To describe the services that exist for referral of women with abnormal smears 
b. To determine waiting times for appointments and treatment at referral centres 
c. To determine the proportion of women with abnormal smears who receive and 
attend appointments at referral centres 
d. To determine where women are lost to follow-up in the screening programme 
 
3. To identify factors associated with attendance of colposcopy appointment, and 
waiting time between Pap smear and colposcopy. 
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CHAPTER TWO 
2. MATERIALS AND METHODS 
 
In this Chapter, the methods used to conduct this study are described.  Details are 
provided on the study setting, design, and the sampling strategy employed.  
Furthermore, the collection of the data is described and the methods of data analysis 
and statistical testing are specified. 
 
2.1 Study Setting 
 
Figure 2.1 Map of the Johannesburg Metro District  
Source: City of Johannesburg, 2008 61 
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The study was conducted in the Johannesburg Metro Health District in the Gauteng 
Province of South Africa, between March 2008 and March 2009.  Johannesburg 
Metro District, a large urban metropolitan district, has a population of approximately 
3.2 million people, with females accounting for 50% (over 1.6 million) of its general 
population.62 It is the most densely populated district in the country, and ranks 
amongst the highest in terms of per capita district health expenditure.63   
 
In line with the national cervical screening policy, Pap smears are provided in the 
district, to women aged 30 years and older accessing primary health care services, at 
no cost.6 A client would have a cervical Pap smear done by facility staff at a primary 
health care (PHC) clinic, and then be asked to return for the result after an interval of 
around three weeks. If an abnormality is detected on the smear that requires further 
investigation and management, she is then instructed to make an appointment at an 
appropriate referral hospital to access colposcopy services. 
 
There is a dedicated data recording tool for collecting cervical screening programme 
data at the clinic level.  The Pap register records client details, Pap smear results and 
referral information where relevant. In addition, information about referrals is 
recorded in a referral book, which contains folio copies of all referral letters issued. 
Monthly collation sheets (used to tally cervical screening information) are also kept at 
the facilities and reported to the DHIS. At the hospitals, all colposcopy appointments 
made are captured in a register, as is a record of those that were attended. This register 
contains client names but no contact details or referring clinic. Some hospitals also 
keep a record of colposcopies performed. 
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2.2 Study Design 
This was a largely descriptive study, involving quantitative methods.  It involved 
secondary analysis of cervical screening data recorded in the DHIS and the National 
Health Laboratory Service (NHLS) databases; and retrospective reviews of monthly 
Pap registers and colposcopy appointment and treatment registers at a sample of PHC 
clinics and their referral colposcopy services in the district. Analytical statistics were 
employed to determine factors associated with colposcopy attendance. 
 
2.3 Sampling 
For the first objective, all cervical screening data reported to the DHIS for the study 
period were included in the analysis. No sampling was done. 
 
For the second and third objective evaluating the referral process, the study sites were 
public sector PHC clinics providing cervical screening services in the district.  The 
study extended to the referral hospitals that patients were directed to for treatment of 
abnormal smears. 
 
The Johannesburg Metro District comprises of seven sub-districts named A to G, 
which collectively have 116 fixed public sector clinics, either run by local 
government (84 clinics), provincial government (30 clinics) or non-governmental 
organisations (NGOs) (2 clinics).  
 
Stratified sampling was employed to select PHC clinics included in this study.  The 
strata were sub-districts A to G, and the three different health authorities (local 
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government, provincial government and NGO).  This ensured that clinics from each 
sub-district, and clinics managed by each authority were represented in the study.   
 
To operationalise the sampling strategy, selection of clinics within the strata was done 
randomly where possible. In each sub-district, one local government and one 
provincial clinic were selected except for two sub-districts (A and B) that do not have 
provincial clinics.  The two NGO-run clinics in the district (in sub-districts A and C) 
were sampled purposively. Thus, a total of fourteen clinics were included in the study 
(Table 2.1).   
 
Table 2.1 Sampling strategy for selecting PHC clinics and referral hospitals 
Fixed Health Facilities by Authority 
Total number (Sample) Sub-
district 
LG Province NGO Total 
 
Hospitals 
A 10 (1) 0 (0) 1 (1) 11 (2)  
B 7 (1) 0 (0) 0 (0) 7 (1) RMH 
C 11 (1) 1 (1) 0 (0) 12 (2)  
D 20 (1) 13 (1) 0 (0) 33 (2) CHBH 
E 9 (1) 1 (1) 1 (1) 11 (3)  
F 14 (1) 3 (1) 0 (0) 17 (2) CMJAH 
G 13 (1) 12 (1) 0 (0) 25 (2)  
Total 84 (7) 30 (5) 2 (2) 116 (14)  
Source: City of Johannesburg, Health Facilities, 2008 64 
 
The sampling strategy also allowed for clinics and their respective referral hospitals to 
be included in the study.  Thus, each of the three hospitals with colposcopy clinics in 
the district (Raheema Moosa, Charlotte Maxeke Johannesburg Academic and Chris 
Hani Baragwanath hospitals) including one hospital in the neighbouring Ekurhuleni 
District (Edenvale Hospital) which received referrals from study sites, were included. 
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It was necessary to include Edenvale Hospital, even though it does not fall within the 
study area, because patients from some clinics located in JMD, were actually referred 
to this hospital in Ekurhuleni, as it was geographically more accessible. 
  
In clinics and hospitals that were selected, all records kept on cervical screening (Pap 
registers, referral letters, monthly collation sheets, colposcopy appointment and 
treatment registers) for the study period were included. 
 
2.4 Data Collection 
To evaluate different components of the cervical screening programme, various data 
sources were used, including: 
 the DHIS database for cervical screening data from Gauteng and JMD 
 the NHLS database for information on Pap smear adequacy 
 DHIS midpoint estimates for target population sizes 
 Pap registers at PHC clinics 
 Colposcopy appointment and treatment registers at referral hospitals 
 
Objective 1: Data were extracted from the DHIS as follows. There are over three 
millions elements related to each process, health outcome and impact indicator stored 
in this database, so a request was made to the Gauteng Department of Health, to 
supply all data relating only to cervical screening for the period April 2000 to March 
2008, for the Gauteng province.  This was supplied in the form of Microsoft Excel 
spreadsheets and pivot tables.  The following data were then extracted from these 
spreadsheets for the Johannesburg Metro District for the 2007/8 financial year (April 
2007 to March 2008): 
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 New screening Pap smears performed per health facility 
 New smears performed for women in each age category, i.e. <20, 20-29, 30-
39, 40-49, 50-59, >60 years 
 Abnormal smears detected in each Pap smear abnormality category, i.e. 
ASCUS, LSIL, AGUS, HSIL, invasive cancer 
 
Data on smear adequacy was requested from the NHLS Cytology department.  This 
was provided as Microsoft Excel spreadsheets and included data for the 2007/8 
financial year only for the fourteen clinics sampled to evaluate the referral process.  
Due to technical difficulties in extracting information on smear adequacy, it was not 
possible for the NHLS to provide data on all clinics in the district. For each clinic, the 
information extracted from the NHLS database included: 
 Number of adequate smears (with endocervical component) 
 Total number of smears screened by the NHLS laboratories 
 
The denominator used for determining the coverage rate was the “population at risk” 
which is defined as the number of women in the target age group above 30 years.  The 
DHIS uses population projections from Statistics South Africa (Stats SA) derived 
from census data, to calculate population denominators for Gauteng and for 
Johannesburg Metro District: 
 Estimated number of insured and uninsured women over thirty years, at the 
midpoint of each year for which coverage was calculated 
The numerator reflects only screening Pap smears done in the public sector, whereas 
the denominator includes insured women (using the private sector) in the target age 
group. Despite this, this formula was employed in this study as it is used by the DHIS 
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to calculate coverage, and this study sought to reflect on the current status of the 
programme in the district. 
 
Objective 2: To describe practices at screening clinics and referral facilities, informal 
interviews were conducted with key staff at each facility, exploring current practices 
with regards to screening and referral. 
 
Objective 2 and 3: involved a review of Pap registers at the selected clinics to identify 
and collect data on women who had Pap smears that were found to have “high grade” 
lesions (HGL) thus requiring referral to colposcopy.  This was followed by a review 
of the colposcopy clinic appointment lists and treatment records to ascertain whether 
these women had made and attended appointments at colposcopy clinics.  For the 
purposes of this study, high grade was defined as any Pap smear that reported high 
grade squamous intraepithelial lesions (HSIL), atypical glandular cells of unknown 
significance (AGUS) or invasive cancers; because routine management protocols state 
that these abnormalities require referral for diagnostic colposcopic procedures.   
 
Data were extracted from clinic Pap registers on women found to have high grade 
lesions on Pap smear during the period April 2007 to March 2008.  The following 
data were captured onto a data collection sheet (Appendix A) adapted from existing 
tools:51 
 Date of Pap smear 
 Name 
 Date of birth; age 
 Contact details (address and telephone number) 
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 HIV status (if available) 
 Pap smear result 
 Date informed of result and referred 
 Referral facility 
 
At the colposcopy clinic, records for the period April 2007 to March 2009 were 
reviewed to ascertain whether the referred women made and attended colposcopy 
appointments. The following data were extracted from the colposcopy clinic records, 
and also entered onto the data sheet in Appendix A: 
 Date of appointment 
 Attendance of appointment 
 
The period that the colposcopy records were reviewed extended to March 2009, to 
allow for a lag time between having a Pap smear and attending a colposcopy 
appointment.  One particular hospital was found to be booking appointments up to 
twelve months later due to large patient volumes.  In line with other studies 
investigating Pap smear follow-up, non-adherent patients are operationally defined as 
patients with abnormal findings on Pap smears who do not have documented 
evaluations or treatments within a specified amount of time, which in this study was 
determined as twelve months. 
 
Every effort was made to confirm that the data collected was complete. In Gauteng 
Province, it was not possible to assess concordance between the Pap registers and 
patient folders as the latter are not retained at the facility. For consistency, multiple 
sources of data were reviewed, where available, at each facility.  At the clinics, the 
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folio copies of referral letters in the referral books confirmed what was recorded in the 
Pap registers.  At the hospitals, both appointment books and treatment records 
(electronic and hard copies where available) were reviewed to capture information on 
colposcopy attendance. 
 
2.5 Data Management and Analysis 
Data from record reviews were coded and captured onto Microsoft Excel 
spreadsheets. To protect the integrity of the database, the Excel data was immediately 
write-protected and stored in two safe places (CD-ROM and dedicated memory stick) 
and then only copies were worked with.  Summary data was examined to detect any 
data errors and once the dataset was found to be “clean”, was then imported to the 
STATA (Release 10, StataCorp, 2007) programme, used to conduct the analysis. 
 
Objective 1: The indicators used to evaluate the screening programme were calculated 
as indicated in Table 2.2. 
 
These indicators, calculated utilising tools previously developed for programme 
managers,51 were compared to programme targets.  The indicators were calculated for 
the district, but in addition the coverage rates were disaggregated for each sub-district.  
Cervical screening coverage and smear abnormality rates were also presented 
according to age category.  In addition, cumulative cervical screening coverage data 
since the inception of the screening programme in November 2000 was presented for 
trend analysis.   
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Table 2.2 Process indicators for evaluating cervical screening programmes 
 
Screening services 
 
Coverage No. of new smears in women > 30 years  x  100 
Total target population 
 
Smear adequacy No. of smears with endocervical component  x  100 
Total no of smears done 
 
Smear abnormality  No. of abnormal smears   x  100 
                             Total no of smears done 
 
 
Client management at primary care level 
 
Clients with abnormal 
smears informed of their 
results 
No. of women with HGL informed of results x 100 
Total no. of women with HGL 
 
 
Colposcopy and treatment services 
 
Colposcopy appointment  No. of women with HGL with colposcopy appointment  x  100 
Total no. of women with HGL 
 
Colposcopy attendance  No. of women who attend colposcopy appointment  x  100 
Total no. of women with HGL 
 
Colposcopy adherence No. of women who attend colposcopy appointment  x 100 
No. of women with HGL informed of results 
 
Source: CHIP, 2004 51 
 
Objective 2: For the evaluation of the referral process, descriptive analysis was 
performed to summarise the characteristics of women from the clinics found to have 
abnormal Pap smears requiring referral.  Proportions and measures of central 
tendency and spread were reported as appropriate for clients’ age, HIV status, and the 
clinic, sub-district or health authority they originated from. 
 
Measures of association determined any differences between sub-districts and health 
authorities.  The chi squared test was used to test for differences in proportions; 
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parametric unpaired Student t-test for comparison between means; non-parametric 
Kruskal-Wallis between medians; and one-way ANOVA with post-test (Tukey) for 
more than three groups of data. Differences in values were considered statistically 
significant if the ‘p’ value was less than 0.05. 
 
In analysing loss to follow-up, methodology employed in a similar study was 
replicated.65 Process effectiveness was measured by the number of appointments set 
up and performance was measured by compliance with referral appointments.  Based 
on published findings on underserved women, three effectiveness cut-off points were 
selected: 80% contact and notification rate, and 72% referral appointment rate for 
system effectiveness, and a 60% appointment compliance rate for system 
performance. These measures were chosen as cut-offs as they were average rates 
found in control groups in studies evaluating interventions aimed at improving 
colposcopy appointment adherence.65 
 
The waiting time for attendance of colposcopy appointment was calculated as the 
difference between date of Pap smear and attendance of colposcopy appointment. 
This interval was selected as it reflected the clients’ complete interaction with the 
health system, and represented the many stages in the screening and referral process 
where women may have been lost to follow-up. 
 
Objective 3: Multivariate logistic regression models were fitted to determine patient 
and health service factors associated with attendance of colposcopy appointments and 
linear regression models were used to determine factors associated with time to 
colposcopy. Possible predictors included age; HIV status; the clinic, health authority 
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and sub-district women were referred from; and the hospital to which they were 
referred. Model building proceeded backwards from a first “full” model including all 
the above variables, from which the non-statistically significant variables were 
withdrawn sequentially. The assumptions of the linear regression model were checked 
by examining the residuals for normality and constancy of spread. 
 
The outcome variables were: 
 Colposcopy attendance (binary) 
 Time to colposcopy (continuous) 
 
The predictor variables included: 
 Age (ordinal) 
 Contact details recorded in Pap register (binary) 
 Clinic (nominal) 
 Health authority (nominal) 
 Sub-district (nominal) 
 Referral hospital (nominal) 
 
2.6 Ethical and Legal Considerations 
Research approval was granted by the Committee for Research on Human Subjects 
(Medical) of the University of the Witwatersrand. Clearance was given for research 
involving patient records (Ethics clearance number: M080439; Appendix B). 
 
This research project was commissioned by the Johannesburg Metro District, Gauteng 
Department of Health.  Access to data in the DHIS was granted by the Health 
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Information Systems Directorate, Gauteng Department of Health.  Managers at the 
Johannesburg Metro District and City of Johannesburg municipality granted 
permission to access the PHC facilities and referral hospitals. Thereafter, permission 
was requested and granted from each sub-district manager, and also from the facility 
managers, prior to visiting the facilities for data collection. 
 
Facility confidentiality was maintained by identification only with a code.  An 
assurance was also made that any pertinent findings would be reported by the primary 
investigator to the managers and staff so that the facility may benefit from 
recommendations arising out of this research study.   
 
For the most part, secondary data did not include patient names.  However, to track 
patients through the referral process, it was necessary to record patient identifiers.  
These were known only to the researcher and all records and documentation were 
housed securely at the School of Public Health, University of Witwatersrand.  
Electronic records were maintained in password-protected computers.  
 
  
37 
CHAPTER THREE 
3. RESULTS 
 
In this Chapter, the study findings are presented. Firstly, results of secondary analysis 
of the cervical screening data from all facilities in the JMD, derived from the DHIS 
are presented. Secondly, primary data collected for this study is presented, on the 
referral of women with high grade lesions and invasive cancer from sampled PHC 
clinics to colposcopy units for diagnosis and treatment. Thirdly, the factors associated 
with colposcopy attendance and waiting times are presented. 
 
3.1 Cervical Screening Indicators 
 
3.1.1 Cervical screening coverage 
Data presented here represents cervical screening data from all 116 primary health 
care clinics and the three hospitals in the district. In each sub-district, the majority of 
clinics belong under the authority of the local government. The distribution of clinics 
by health authority type is depicted in Table 3.1. 
 
Table 3.1 Distribution of PHC clinics by health authority, JMD 
Sub-district LG Province NGO Total Proportion LG 
A 10 0 1 11 91% 
B 7 0 0 7 100% 
C 11 1 0 12 92% 
D 20 13 0 33 61% 
E 9 1 1 11 82% 
F 14 3 0 17 82% 
G 13 12 0 25 52% 
Total 84 30 2 116 72% 
Source: City of Johannesburg, Health Facilities, 2008 64 
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a. Cumulative coverage 
The cumulative coverage data includes only screening data on women as defined by 
the national programme, i.e. women who are 30 years old and above.  Figure 3.1 
describes the trend in the cumulative cervical screening coverage for the 
Johannesburg Metro District and Gauteng Province since the programme inception in 
2000 until the end of the 2007/8 financial year (March 2008).  The coverage required 
to attain the national target of 70% cumulative coverage by 2010, indicated by the 
straight line, is shown for comparison.  Cumulative coverage for JMD (30.7%) is 
higher than the provincial average (21.4%).  Cumulative cervical screening coverage 
in both the district and the province are below national targets. 
 
Figure 3.1 Cumulative cervical screening coverage: JMD, Gauteng 2000 – 2008 
 
The cumulative cervical screening coverage by March 2008, shows significant 
variation across the districts of the Gauteng Province and the sub-districts in JMD.  
Two of the metropolitan districts, JMD and Ekurhuleni, have the highest coverage in 
the province (Figure 3.2), and sub-districts A and C have the highest cumulative 
coverage in the JMD (Figure 3.3). 
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Figure 3.2 Cumulative screening coverage: districts in Gauteng province, 2008 
 
 
Figure 3.3 Cumulative screening coverage: sub-districts in JMD, 2008 
 
b. Pap smears per clinic 
Table 3.2 shows that of all Pap smears reportedly performed for women over 30 years 
in 116 PHC clinics and 3 hospitals in 2007/8, a median of 267 smears were performed 
per health facility in the district in that year, with NGO clinics performing most 
smears per facility, followed by local government then provincially-run health 
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facilities.  The differences between health authority was statistically significant 
(p<0.001). 
 
Table 3.2 Distribution of all smears done in JMD, 2007/8 
Health Authority (n) Median Range 
Local govt (84) 296 6 – 749 
Provincial govt (33) 153 0 – 874 
NGO (2) 581 471 – 690 
All (119) 267 0 – 874 
 
 
3.1.2 Appropriate age for screening 
Figure 3.4 demonstrates the number of Pap smears done in JMD, by age group.  Data 
for three financial years (2005/6 to 2007/8) are presented to demonstrate a trend over 
time.  The highest number of Pap smears were done in women aged 30-39 and those 
aged 40-49, with lower numbers of smears done in older age groups.  The data also 
shows that smears are being done in younger women who are outside the target age 
group for the cervical screening programme.   
 
Figure 3.4 Number of Pap smears done by age group: JMD, 2005-7 
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As shown in Figure 3.5, Pap smears in women less than 30 years of age consistently 
accounted for about 21% of all smears done in each of the three years.   
 
Figure 3.5 Proportion of smears done in target age group: JMD, 2005-7 
 
3.1.3 Cervical screening loss to follow up 
The health facilities report information on the numbers of patients who do not return 
for their Pap smear results to the DHIS, and these are defined as women lost to 
follow-up.  Large proportions of women across every age group do not return to the 
clinics for their results.  In Figure 3.6, there is a trend of increasing loss to follow up 
from 2005 to 2007 for each age group (chi squared test for trend p=0.046). An 
average of 30% loss to follow up is seen in 2005 and 2006, but this increased to 
almost 36% in 2007.  
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Figure 3.6 Proportion of clients lost to follow-up: JMD, 2005-7 
 
3.1.4 Cervical smear abnormality 
In 2008, of 63 327 Pap smears done in the Johannesburg Metro District, 10.7% were 
found to be abnormal. Figure 3.7 shows that of the total Pap smears done each year, 
low grade lesions (including LSIL and ASCUS) are more commonly seen than high 
grade lesions (including HSIL and invasive cancer) and AGUS. 
 
Figure 3.7 Proportion of smears with low and high grade lesions: JMD, 2005-7 
 
Of the total high grade lesions detected, 17% (550 of 3 154) were in women less than 
30 years. Figure 3.8 describes the distribution of abnormal smears amongst different 
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age groups for 2007/8.  With increasing age, a smaller proportion of smears show low 
grade lesions.  4.4% (2 395 of 63 327) of women less than 30 years had high grade 
lesions or invasive cancer. 
 
Figure 3.8 Proportion of Pap smear abnormalities by age group: JMD, 2007/8 
 
To demonstrate more clearly the abnormalities by age group, data from 2007/8 only 
are presented in the figures below.  During this period, 7 403 smears were abnormal, 
of which 1 699 (23.0%) were in women aged less than 30 years and 5 704 (77.0%) in 
women older than 30 years. Up to 71% of all abnormal smears in the under 30 years 
age group are low grade, whereas 56 – 58% were low grade at older ages. Conversely, 
a higher proportion of abnormal Pap smears in older ages show high grade lesions and 
cancers compared to younger women (Figure 3.9). 
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Figure 3.9 Proportion of low and high grade lesions by age group: JMD, 2007/8 
 
 
3.2 Referral to Colposcopy Services 
 
3.2.1 Cervical smear adequacy 
During April 2007 and March 2008, 4 723 Pap smears were done in the 14 clinics 
sampled for the study. The adequacy rates of these smears are presented in Figure 
3.10 and compared to the target of 70% contained in the national guidelines. 
 
Figure 3.10 Smear adequacy rates in sampled clinics, JMD, 2007/8 
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3.2.2 Clinic screening practices 
During data collection for this study, varying practices with regard to screening were 
observed at the sample clinics. One particular clinic manager held two large “cervical 
screening days” during the year.  Community based health care workers raised 
community awareness of the screening drives, and clinic staff were mobilised to 
provide the service after-hours on a Saturday.  Ultimately, hundreds of Pap smears 
were performed on those two days in the year. In some clinics, managers used 
screening targets each month, and this ensured a concerted effort was made to 
perform a certain number of Pap smears monthly. The latter practice may relate to 
practices of the authority running the clinic- local government clinics have 
“scorecards” to monitor performance over many service areas and these translate into 
target setting for the clinics. Many facilities targeted women attending family 
planning clinics for cervical screening, resulting in large proportions of Pap smears 
being done in young women in the reproductive age groups.   
 
3.2.3 Detection of high grade lesions 
Review of the clinic Pap registers from 14 clinics showed 557 women with high grade 
lesions, out of 4 723 total Pap smears performed.  Table 3.3 displays the number of 
women with high grade lesions by clinic and Table 3.4 by health authority.  The 
NGOs identified the highest percentage of women with high grade lesions requiring 
referral (Table 3.4). 
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Table 3.3 Distribution of high grade lesions by clinic  
Clinic No of smears No of high grade 
lesions 
Proportion 
high grade % 
A LG 415 29 7.0 
A NGO 747 111 14.9 
B LG 167 23 13.8 
C LG 249 17 6.8 
C PROV 347 47 13.5 
D LG 379 54 14.2 
D PROV 216 35 16.2 
E LG 470 40 8.5 
E NGO 538 96 17.8 
E PROV 273 8 2.9 
F LG 372 33 8.9 
F PROV 73 3 4.1 
G LG 238 30 12.6 
G PROV 239 31 13.0 
TOTAL 4 723 557 11.8 
 
Table 3.4 Distribution of high grade lesions by health authority 
Health Authority 
 
No of smears No of high 
grade lesions 
% HSIL 
LG 2290 226 9.9 
NGO 1285 207 16.1 
Provincial 1148 124 10.8 
TOTAL 4723 557 11.8 
 
Figure 3.11 shows the number of high grade lesions detected by a clinic correlates 
with the number of Pap smears performed (Spearman’s rho= 0.70; p=0.005). 
0
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Figure 3.11 Correlation between Pap smears performed and HGLs detected 
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3.2.4 Descriptive analysis of women with high grade lesions 
The following is a description of selected demographic and clinical characteristics of 
the 557 women who were found to have high grade lesions on Pap smear. 
 
a. Age 
The mean age of women with high grade lesions was 36.2 (SD 9.2) years, exhibiting a 
range of 17 to 77 years.  20.6% of these women were under 30 years of age (Figure 
3.12). There were significant differences in the ages of women with high grade 
lesions at the various clinics sampled (p=0.004).  Women screened by the provincial 
clinics have a higher mean age than the other clinics (p<0.001). 
 
Figure 3.12 Distribution of high grade lesions by age group 
 
b. HIV status 
HIV status was not routinely recorded in the Pap registers or referral letters, and the 
data presented includes only those that were known and recorded to be HIV infected. 
An HIV positive diagnosis was noted in 118 out of 557 women (21%), while the HIV 
status of the rest of the women with high grade lesions were unknown. 
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The percentage of high grade lesions in HIV positive women by clinics is shown in 
Figure 3.13. Three clinics detected HSIL and cancer in large proportions of HIV 
positive women. A(NGO) did Pap smears primarily for pre-screening for ART. The 
majority of Pap smears done at G(Prov) were in the ART clinic. E(Prov) reported 
prioritising cervical screening in HIV positive women. 
 
Figure 3.13 Proportion of high grade lesions in HIV positive women, by clinic 
 
From the results presented above, a distinction can be made between clinics 
conducting screening of HIV positive women (for pre-ART initiation and routine 
annual follow-up), and those doing general screening of the target age group. Table 
3.5 shows the difference in age between HIV-screening (HIV positive women) and 
general screening (unknown HIV status), in the 539 clients whose ages were recorded. 
Women identified with HSIL from HIV clinics were on average younger than those 
picked up from routine screening. This difference was statistically significant 
(p=0.045). 
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Table 3.5 Relationship between age and HIV status in women with HGLs 
Screening setting  (n) Mean age 95% CI p-value 
HIV screening (112) 34.65 33.31 – 35.99 
General screening (427) 36.60 35.69 – 37.52 
0.045 
 
 
3.2.5 Data recording 
 
a. Contact details 
Figure 3.14 shows that contact telephone numbers were recorded in the clinic Pap 
registers for 269 of 557 (48%) women with high grade lesions. 
 
Figure 3.14 Proportion of clients in whom contact details were captured (N=557) 
 
The percentage of women for whom contact details were recorded varied significantly 
between different clinics ranging from 0% to 100% (Figure 3.15); and by health 
authority (Figure 3.16). Provincial clinics were most likely to record contact numbers 
(82; 66.1%), followed by NGO (91; 44.0%) and local government (96; 42.5%) clinics. 
The differences were statistically significant (p<0.001). 
  
50 
 
Figure 3.15 Proportion of contact details recorded, by clinic 
 
Figure 3.16 Proportion of contact details recorded, by health authority 
 
b. Completeness of results entered in Pap register 
Record keeping was further assessed by determining the number of Pap smears done 
and the number of results entered in the Pap register. This was compared for each 
clinic, and is displayed in Figure 3.17. On average, 84.7% of Pap smear results had 
been entered in the Pap register, and this ranged from 40.2% to 98.8% between 
clinics.  There was no statistically significant differences in data completeness 
between health authorities (p=0.38) or sub-districts (p=0.44). 
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Figure 3.17 Proportion of results entered into Pap register, by clinic 
 
3.2.6 Referral hospital 
The 14 study sites refer women to four hospitals for colposcopy. These include Chris 
Hani Baragwanath Hospital (CHBH), Raheema Moosa Hospital (RMH), Charlotte 
Maxeke Johannesburg Academic Hospital (CMJAH) and Edenvale Hospital (EH). 
 
a. Practices and activities at referral hospitals 
Each referral hospital had a very different capacity and pattern of colposcopy activity. 
CHBH has an extremely busy colposcopy clinic, operating each weekday, Monday to 
Friday, performing on average 100 to 120 colposcopies per week.  The time to next 
available booking is nine months.  Appointments are generally made directly by the 
referring facility staff via a telephone call to the colposcopy clinic. At RMH, twenty 
colposcopies are done per week on four days in the week.  Clients have to present 
themselves at the colposcopy clinic to make an appointment, and may have to wait 
about two months for a booking. CMJAH sees about thirty to forty patients per week, 
each day of the week.  Clients make their own appointments, and the current waiting 
time for booking an appointment is around four months. EH, during the time the study 
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was conducted, were operating a very inconsistent colposcopy service due to issues 
with the functioning of equipment.  They did only six to seven colposcopies on 
average per month.  Clients made their own appointments and were given bookings 
within two to three months. 
 
All hospitals use colposcopy booking registers that record client names only. No 
contact details are captured for patients in any of the registers. Defaulters were neither 
traced by the colposcopy clinic, nor reported to the referring PHC clinics. 
 
b. Referral of clients with high grade lesions 
Of the 557 high grade lesions detected, 318 women were given their results and 
referred for colposcopy. Women with high grade lesions in this study were referred to 
the following hospitals for colposcopy: CHBH (111; 35%), RMH (134; 42%), 
CMJAH (67; 21%) and EH (6; 2%). Clinics referred patients to the various hospitals 
according to geographic location, and there was no difference in referral patterns on 
the basis of health authority. Consistently, each hospital received referrals from 
certain sub-districts – RMH (sub-districts A, B and C), CMJAH (sub-districts E and 
F), EH (sub-district E), and CHBH (sub-districts D and G). 
 
3.2.7 Time to colposcopy 
Of 318 women referred, 211 made appointments and 155 attended colposcopy clinic. 
The median time between Pap smear and attendance at colposcopy clinic was 4.4 
months (IQR 3.1 – 7.1 months), ranging from 1.0 to 15.4 months.  Clinics referring to 
the same hospital generally had similar waiting times to colposcopy appointment 
(Figure 3.18).   
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Figure 3.18 Median time to colposcopy, by clinic 
 
Table 3.6 shows that there was no difference in median time to colposcopy between 
clinics under different authority (p=0.370), but there was variation by sub-district 
(p<0.001) and referral hospital (p<0.001).  
 
Table 3.6 Median time to colposcopy attendance  
 Time to colposcopy (months) 
median (IQR)  
p-value 
Health authority 
LG 
NGO 
Provincial 
 
4.6 (3.1 – 7.6) 
4.3 (3.1 – 6.3) 
4.1 (2.8 – 6.5) 
 
0.370 
 
Sub-district 
A 
B 
C 
D 
E 
F 
G 
  
4.3 (3.1 – 5.9) 
2.8 (2.0 – 4.5) 
2.8 (2.1 – 3.5) 
7.0 (4.7 – 8.4) 
4.5 (3.1 – 6.3) 
3.7 (3.5 – 4.0) 
7.5 (6.0 – 11.2) 
 
<0.001 
Referral Hospital 
CHBH 
RMH 
EH 
CMJAH 
 
7.3 (4.9 – 8.8) 
3.5 (2.5 – 5.0) 
3.2 (2.2 – 4.4) 
4.5 (3.5 – 6.7) 
 
<0.001 
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3.2.8 Loss to follow-up 
Of all 557 women identified to have pre-cancerous and cancerous lesions on Pap 
smear, 155 attended diagnostic and treatment facilities. Figure 3.19 describes where 
women were lost to follow-up in the cervical screening and treatment process. In 
measuring system effectiveness, the notification rate was 57% and referral 
appointment rate was 38%, and for system performance the appointment compliance 
rate was 28%.  
 
 
 
 
 
 
Figure 3.19 Loss to follow up of women with high grade lesions 
 
There were significant differences between health authority and sub-district with 
regard to system effectiveness and performance (Table 3.7). While provincial clinics 
(83.9%) referred high proportions of women with high grade lesions, local 
government (48.2%) patients were most likely to make appointments, and provincial 
(32.3%) patients were most likely to attend colposcopy appointments. NGO-run 
clinics performed poorest in terms of referral of women to colposcopy services. 
 
High grade 
lesions 
 
557 
 
Referred to 
colposcopy 
 
318 
57% 
Colposcopy 
appointment 
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Colposcopy 
appointment 
 attended 
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28% 
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Sub-district B referred (87.0%) the highest proportion of women requiring 
colposcopy, and also had the highest proportion who attended their appointments 
(43.5%). Patients from sub-district E were least likely to be referred (34.7%), make 
appointments (19.4%) or attend appointments (15.3%). 
 
Table 3.7 Differences in system effectiveness and performance  
 
HSIL 
n 
Referred 
n (%) 
Appointment 
n (%) 
Attended 
n (%) 
Health  Authority 
 
LG 
NGO 
Provincial 
226 
207 
124 
p<0.001 
 
153 (67.7) 
61 (29.5) 
104 (83.9) 
p<0.001 
 
109 (48.2) 
51 (24.6) 
51 (41.1) 
p=0.259 
 
65 (28.8) 
50 (24.2) 
40 (32.3) 
 
Sub-district 
 
A 
B 
C 
D 
E 
F 
G 
140 
23 
64 
89 
144 
36 
61 
p<0.001 
 
60 (42.9) 
20 (87.0) 
55 (85.9) 
65 (73.0) 
50 (34.7) 
23 (63.9) 
45 (73.8) 
p<0.001 
 
52 (37.1) 
10 (43.5) 
25 (39.1) 
50 (56.2) 
28 (19.4) 
17 (47.2) 
29 (47.5) 
p<0.001 
 
52 (37.1) 
10 (43.5) 
24 (37.5) 
25 (28.1) 
22 (15.3) 
3 (13.9) 
17 (27.9) 
 
 
3.2.9 Colposcopy adherence 
Colposcopy adherence reflects the proportion of women who were given their results 
and referred, and who then attended colposcopy appointments. Adherence ranged 
from 0% to 100%. Clinics differed significantly in adherence rates (Figure 3.20), with 
only A(NGO) achieving an adherence rate over 70%. Patients referred from NGO 
clinics had highest adherence of 82%, and patients from local government (42.5%) 
and provincial clinics (38.5%) had lower adherence rates (Figure 3.20). 
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Figure 3.20 Colposcopy adherence rates, by clinic 
 
 
3.3 Predictors of Colposcopy Attendance 
On univariate analysis, sub-district, HIV seropositivity and recording of contact 
telephone number were associated with attending colposcopy appointment. Age and 
health authority were not statistically significant variables. Patients from sub-districts 
E and F were less likely to attend, compared to those from sub-district A; and women 
who were HIV positive and those whose contact telephone numbers were recorded 
were more likely to attend appointments (Table 3.8). 
 
In the multivariate logistic regression model, health authority, sub-district and HIV 
seropositivity were significantly associated with colposcopy attendance. Patients from 
NGO clinics were less likely to attend appointments. Compared to sub-district A, 
patients from F were less likely to attend. HIV positive women were still more likely 
to attend appointments than those in whom HIV status was unknown.  Recording 
contact details in the Pap register was associated with a higher chance of attending 
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colposcopy, but this was not found to be significant (p=0.090). Age did not influence 
attendance of colposcopy appointment (Table 3.8). 
 
Table 3.8 Predictors of colposcopy attendance at referral hospitals 
Univariate Analysis Multivariate Analysis  
OR (95% CI) p value OR (95% CI) p value 
Health  Authority 
LG 
NGO 
Provincial  
 
1 
0.8 (0.5 – 1.2) 
1.2 (0.7 – 1.9) 
 
- 
0.279 
0.495 
 
1 
0.4 (0.2 – 0.7) 
1.0 (0.6 – 1.9) 
 
- 
0.005 
0.892 
Sub-district 
A 
B 
C 
D 
E 
F 
G 
 
1  
1.3 (0.5 – 3.2)  
1.0 (0.6 – 1.9) 
0.7 (0.4 – 1.2) 
0.3 (0.2 – 0.5) 
0.3 (0.1 – 0.7) 
0.7 (0.3 – 1.3) 
 
- 
0.563 
0.961 
0.159 
0.000 
0.011 
0.205 
 
1 
1.2 (0.4 – 3.6) 
0.8 (0.3 – 1.9) 
0.6 (0.2 – 1.3) 
0.6 (0.3 – 1.3) 
0.3 (0.1 – 0.9) 
0.5 (0.2 – 1.2) 
 
- 
0.697 
0.563 
0.159 
0.174 
0.035 
0.117 
Age 
<30 
30-39 
40-49 
50-59 
>60 
 
1 
1.4 (0.9 – 2.4) 
1.4 (0.8 – 2.5) 
0.8 (0.3 – 2.2) 
1.6 (0.5 – 5.9) 
 
- 
0.159 
0.285 
0.692 
0.451 
  
HIV 
Unknown 
Positive 
 
1 
2.1 (1.4 – 3.3) 
 
- 
0.001 
 
1 
2.4 (1.3 – 4.5) 
 
- 
0.007 
Contact details 
Not recorded 
Recorded 
 
1 
2.4 (1.6 – 3.5) 
 
- 
0.000 
 
1 
1.6 (0.9 – 2.6) 
 
- 
0.090 
 
 
Factors associated with long waiting time  
The univariate analysis presented in Table 3.9 revealed sub-district and referral 
hospital to be associated with longer lag times between Pap smear and colposcopy 
attendance. Health authority, age, HIV status and recording of contact details showed 
no association with duration of time to attendance of appointment. Patients from sub-
district C had the shortest waiting times. Compared to Chris Hani Baragwanath 
Hospital, the other hospitals had 2.1 to 3.8 months shorter waiting times (p<0.006). 
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On multivariate analysis, sub-district was dropped due to colinearity with referral 
hospital (as previously discussed), and only the hospital to which a woman with a 
high grade lesion was referred, remained a significant predictor of time to colposcopy 
attendance (Table 3.9). 
 
Table 3.9 Predictors of waiting time from Pap smear to colposcopy 
Univariate Analysis Multivariate Analysis  
coeff (95% CI) 
difference (mo) 
p value coeff (95% CI) 
difference (mo) 
p value 
Health  Authority 
LG 
NGO 
Provincial  
 
1 
-0.8 (-1.9 – 0.3) 
-0.3 (-1.5 – 0.9) 
 
- 
0.161 
0.667 
  
Sub-district 
A 
B 
C 
D 
E 
F 
G  
 
1  
-1.3 (-3.1 – 0.5)  
-1.8 (-3.1 – -0.5) 
2.2 (1.0 – 3.5) 
0.3 (-1.0 – 1.6) 
-0.6 (-3.0 – 1.9) 
3.1 (1.7 – 4.6) 
 
- 
0.144 
0.008 
0.001 
0.638 
0.640 
0.000 
  
Age 
<30 
30-39 
40-49 
50-59 
>60 
 
1 
-7.6 (-1.9 – 0.4) 
-0.03 (-1.3 – 1.3) 
0.4 (-1.8 – 2.6) 
-0.03 (-3.0 – 2.9) 
 
- 
0.206 
0.964 
0.726 
0.985 
  
HIV 
Unknown 
Positive 
 
1 
0.1 (-1.0 – 1.1) 
 
- 
0.888 
  
Contact details 
Not recorded 
Recorded 
 
1 
-0.5 (-1.5 – 0.5) 
 
- 
0.294 
  
Referral Hospital 
CHBH 
RMH 
EH 
CMJAH 
 
1 
-3.2 (-4.2 – -2.2) 
-3.8 (-6.1 – -1.5) 
-2.1 (-3.5 – -0.6) 
 
- 
0.000 
0.001 
0.005 
 
1 
-3.2 (-4.2 – -2.2) 
-3.8 (-6.1 – -1.5) 
-2.1 (-3.5 – -0.6) 
 
- 
0.000 
0.001 
0.005 
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CHAPTER FOUR 
4. DISCUSSION AND LIMITATIONS 
 
4.1 Discussion 
In this chapter, the results obtained from the analysis of the study data are discussed 
and interpreted in light of other published studies. 
 
This study shows that the cumulative cervical screening coverage for the period 2000 
to 2008 is below target for both the district (30.7%) and the province (21.4%). A high 
number of Pap smears continue to be performed in women less than 30 years, who are 
outside the target age group according to the national policy. Despite this, a relatively 
significant proportion of high grade lesions and invasive cancers (4.4%) are detected 
in young women.  In evaluating referral to colposcopy, there is a high loss to follow 
up, with only 28% of women with high grade lesions and invasive cancers detected at 
Pap smear, attending colposcopy appointments. Long waiting times between Pap 
smear and colposcopy, up to 15 months, were noted. Differences in practice and 
procedures between individual clinics, between referral hospitals, as well as between 
health authorities, contribute to differences within the district in system effectiveness 
and performance. 
 
4.1.1 Cervical screening coverage 
This analysis demonstrated a low cumulative coverage of cervical screening in the 
Johannesburg Metro District, and in the Gauteng province.  By a considerable margin, 
both the district and the province are not on target to achieve 70% coverage that was 
planned for the first ten years of the national programme. This finding is supported by 
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other studies that have revealed low coverage of cytology-based screening 
programmes in developing countries,66,67 including South Africa.51,68,69 It is reported 
that only 5% of women in developing countries undergo cervical screening compared 
with 40% to 50% in the developed world.70 Population-based surveys showed that 
cervical cancer screening coverage in developing countries is on average 19%, 
compared to 63% in developed countries, and ranges from 1% in Bangladesh to 73% 
in Brazil.71 Considerable inequalities in screening coverage exist across global wealth 
deciles, while women at the highest risk of developing cervical cancer are among the 
least likely to be screened.  In a cervical screening programme, it is only through 
ensuring a high coverage rate (over 80%) of the target population, that any benefits 
will be seen in reduction of incidence and mortality from cervical cancer.4,5 
 
However, it is evident that while coverage is well-below target, there does appear to 
be a sharper increase in more recent years.  This is possibly due to increased efforts at 
improving screening coverage in recent years by the Gauteng Department of Health, 
following recommendations by a large multicentre study that evaluated the 
implementation of the programme, and instituted follow-up training for programme 
and facility staff.51 Another possible reason is increased funding and prioritisation of 
cervical screening in the province, evidenced by then-Health Member of the 
Executive Council (MEC) of the Gauteng Province, Dr Gwen Ramokgopa’s 
announcement of an R8 million budget allocation for cervical screening in 2001/2.72 It 
should be borne in mind that if coverage is increased to required levels to meet 
programme targets, the implications of increasing current levels of screening would 
necessitate commensurate increases in levels of funding, infrastructure, staffing, and 
laboratory capacity to be made available.  
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While this study has presented data to assess the current coverage status, it has not 
attempted to determine the reasons for the low screening coverage.  Other research 
has attributed low uptake of cervical screening to firstly patient factors including poor 
public knowledge and awareness of the need for cervical screening.4,73 Women report 
lack of family support, fear, anxiety, lack of understanding of the Pap smear test and 
fatalistic attitudes (not wanting to know if one has cancer).4,73   
 
Secondly, there are health system barriers to accessing preventive health services 
including health workers attitudes and practices,51,52,74 and programmatic 
challenges.42,49 In South Africa, there is a shortage of clinic staff,75 and nurses report 
reluctance to offer Pap smears for fear of increasing their workloads.13,51  Many 
nurses disagree with the policy recommendation on the screening interval and target 
age for screening. In one study, 84% of nurses were opposed to the 10-year policy as 
they believed cancer could develop during the screening interval. The vast majority 
interviewed felt that screening should occur every three to five years, starting before 
age 30.8 After an intervention involving training and explanation of the rationale for 
the policy, nurses’ ability and willingness to provide screening increased. This 
resulted in an increase in coverage and an increase in the proportion of smears done in 
the target age group.8 This highlights the need for interventions to address quality 
concerns, knowledge, skills, attitudes and willingness to provide services.10 
 
Some authors have attributed the low testing rates in some countries that use 
cytological screening to poor programmatic quality and lack of programme 
management skills.42,49,66,76 Even in the United Kingdom, a developed country, prior 
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to introduction of an organised national programme, the cervical cancer screening 
system was ineffective due mainly to organisational problems.  Most cytological tests 
had been performed opportunistically on women presenting for gynaecological 
consultation. At least two-thirds of women with invasive cervical cancer had never 
been screened, and more than 90% of women over 40 years of age had never been 
screened.77   
 
The concept of “informed uptake” is gaining acceptance worldwide- achieving high 
uptake rates while ensuring that patients are making informed choices and are aware 
of all the risks and benefits of participation.78 Some interventions that have been 
shown to improve coverage include personal invitation letters, but these are noted to 
be difficult to implement in low-resource setting..4,78 Community strategies have been 
employed to varying success.79,80 In some settings a multimodal combination of 
community health worker (CHW) outreach and media exposure produced large 
increases in Pap testing.74,81 Media-based campaigns can produce short-term and 
geographically specific increases in uptake, but evidence for their effectiveness in 
leading to sustained increases is varied.4 Inclusion of cancer-related material in 
popular television series has shown pronounced short-term effects on screening 
uptake.78 Efforts aimed at client recruitment within the health facilities and from the 
communities, as well as mass awareness campaigns using the media, have been 
effective in bringing women into the clinics to have Pap smears.79  
 
Variation in coverage in Gauteng Province 
Marked variation was noted in screening coverage between the districts in the 
Gauteng Province as well as between the sub-districts in the Johannesburg Metro 
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District.  From the provincial comparison, Johannesburg Metro District performs 
significantly better than the other districts, with Tshwane, West Rand and 
Metsweding having very low cumulative screening coverage.  These variations are 
concerning and may suggest continuing inequity in delivery of cervical screening 
services. A study in the mid-1990s in the Western Cape, South Africa, showed 
inequity in screening practices for different age groups as well as for geographical 
settings, with metropolitan areas having higher screening rates.82 Research suggests 
that women living in urban areas are more likely to attend for screening.4 Other 
reviews elsewhere have noted that cancer screening is underutilised by ethnic 
minorities, persons living in rural areas, the poor, the uninsured, and the elderly.56 In 
this study, the low coverage in Metsweding and West Rand could be explained by the 
fact that large parts of these districts are rural, but the low coverage in Tshwane is 
difficult to understand as it is a large, metropolitan district. 
 
The District Health Barometer presents a valuable comparison across the districts in 
South Africa on a wide range of indicators.  The finding of better cervical screening 
coverage by JMD compared to other districts, is consistent with other indicators 
showing this district to maintain superior performance with relation to TB cure rates 
and immunisation coverage, and lower incidences of diarrhoeal disease and children 
under five not gaining weight.63  JMD belongs to the top socio-economic quintile and 
amongst least deprived districts that generally demonstrate better health outcomes.63  
There are numerous possible reasons, as a district requires adequate budgetary 
allocation, sufficient human and other resources, efficient management, and good 
systems in place to function smoothly.  According to the District Health Barometer, 
JMD is ranked tenth of 52 districts nationally, in terms of non-hospital primary health 
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care spending, well above the national average.63  Historically, the larger metropolitan 
districts have benefited from better staffing and budgets than other districts, and 
although these differentials are being narrowed, it is still fair to say that a large, highly 
populated urban district like JMD, which is well-served in terms of health facilities 
and resources, may have better service outcomes than other districts even within the 
province.  It is unsure why Tshwane should be among the poorer performing districts 
in the province. It is a metropolitan district in socio-economic quintile four, performs 
relatively well on PHC expenditure, 63 and has a greater supply of health facilities and 
human resources available than the smaller districts in the province. Tshwane also 
performs poorly in PHC utilisation rate, antenatal HIV testing, and stillbirth and 
perinatal mortality rate.63  
 
Another factor that may explain differences between districts is the differences there 
may be in management style.  Very often, a champion manager who prioritises a 
certain programme may see results of better performance in that selected programme.  
Other programmes (e.g. TB, HIV, etc) have reported similar differences between 
districts which have been ascribed to better and more innovative management and 
leadership by an internal change agent who becomes an “early adopter”.83 
 
There were also differences in coverage between the sub-districts in JMD, ranging 
from a low of 22% (sub-district E) to highs of 44% (sub-district C) and 48% (sub-
district A).  Sub-districts A and C have more local government clinics.  There could 
be differences in management style, staffing and programmatic practice, between 
local government and provincial-run clinics and also at sub-district level. Historically, 
preventive services were core to municipal health functions, and these clinics also had 
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a higher attendance of young females who attended for family planning services. It 
may be that these historical differences still persist, resulting in higher screening rates 
in LG compared to provincial clinics. 
 
Clinics that perform higher volumes of screening Pap smears are likely to pick up a 
higher proportion of abnormalities.  Increased levels of screening in an unscreened 
population, leads to higher rates of abnormalities detected.  
 
Individual clinic practices contribute significantly to their performance in respect of 
smears performed. Some anecdotal findings from the data collection efforts support 
the assertion that champion managers at facility level have the potential to positively 
influence screening coverage.  The clinic that held screening drives and the ones that 
use monthly targets are able to increase the numbers of Pap smears performed beyond 
what is routinely achievable.  
 
4.1.2 Screening in women less than 30 years 
This study demonstrated that each year, over 20% of the total Pap smears recorded in 
the district, are done on women less than 30 years of age, despite the national policy 
stating that screening should target women over the age of 30 years.  This finding has 
also been observed in other studies in South Africa.8,13,51,54 It is suggested that this 
may be due to healthcare workers’ lack of knowledge and acceptance of the policy, 
even after training.51 In many countries, paradoxically, coverage rates decline with 
advancing age, when cervical cancer incidence rates are the highest.71 In this study, 
many facilities primarily targeted women attending family planning clinics or HIV 
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positive women starting ART for cervical screening, and therefore did large numbers 
of smears on young women neglecting higher risk older women.   
 
The national cervical screening policy recommends screening in women 30 years and 
older. Studies have clearly shown that cytological screening in women aged 20-34 
years is less effective at preventing invasive cervical cancer than it is in older 
women.84,85  Also, extending screening to younger age groups would result in a 
greater amount of low-grade disease detected and hence, a larger number of women 
made anxious,86 and importantly for the health system, an increase in excessive 
colposcopy referral.87   
 
In line with WHO recommendation, the South African national policy was a rational 
attempt to ensure high coverage of the high risk target age group, by decreasing the 
frequency of smears. By continuing to do a large number of smears on relatively low-
risk younger women, resources are diverted from the actual target population for the 
screening programme.   
 
Most recent International Agency for Cancer Research (IARC)4 and WHO5 
recommendations state that new programmes should start screening women aged 30 
years or more, and include younger women only when the higher-risk group has been 
covered. Existing organised programmes should not include women less than 25 years 
of age in their target populations, and if a woman can be screened only once in her 
lifetime, the best age is between 35 and 45 years. Age is the most important risk factor 
for cervical cancer and screening should aim to target high-risk women.4 
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Interestingly, despite a clear policy in place that addresses this, debates are still 
ongoing on the optimal age to initiate cervical screening, and a senior manager in the 
Gauteng Department of Health’s Mother and Child Directorate, has stated recently 
that the province intends dropping the age at which screening should commence to 25 
years.88 
 
However, this is contradictory to expert opinion, that argues for countries to first scale 
up coverage in the high risk older age groups, before extending to younger women 
and increasing the frequency of Pap smears.4,5 It is a concern that targets in South 
Africa are not being met for the current age groups to be screened, so dropping the 
age at which to begin screening would serve only to strain the programme even 
further.  The resultant increase in the burden on the health system and the laboratories, 
if a hugely increased volume of smears would need to be done, has not been 
estimated. It is necessary to first address the reasons for not achieving current 
screening coverage targets, including health workers practices and uptake of services. 
In addition, it should not be forgotten that cervical screening prevention is about more 
than just doing Pap smears and also requires effective management and treatment of 
high grade lesions. 
 
4.1.3 Screening in HIV positive women 
This study found that 20% of women in whom high grade lesions were detected, were 
documented as being HIV positive.  Other studies have also shown an almost 6 times 
higher risk of showing HSIL on Pap smear in HIV infected women.23 South African 
studies have found an exceptionally high prevalence of cervical abnormalities in HIV 
positive women of up to 66%,89 especially in women less than 30 years.27 In keeping 
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with other studies,23 and notwithstanding limitations of the data, our study also 
showed that women with high grade lesions who were HIV positive were on average 
younger than those in whom HIV status was unknown. 
 
Another observation when conducting this study was that some clinics were doing 
Pap smears almost exclusively on HIV positive women for pre-screening prior to 
initiation of ART.  These facilities were conducting little or no general screening for 
cervical cancer in high risk older age groups.  
 
The high prevalence of cervical abnormalities in HIV positive women has major 
health planning and resource implications, particularly as coverage of ART increases 
in South Africa.89 Theoretically, cervical cancer prevention services should be 
integrated within the platform of HIV/AIDS care and treatment programmes in 
countries like South Africa, which have a dual burden of HIV and cervical cancer.90  
Women who are screened and found to have SILs should also be offered HIV 
voluntary counselling and testing.23 
 
The current practice in HIV/AIDS clinical management is for annual screening of 
HIV-positive women who are immune compromised (CD4 <350).9 A serious gap 
exists in the national cervical screening policy and guidelines, as it does not explicitly 
address the issue of screening in HIV positive women.91 The IARC reports that HIV-
positive women may benefit from more frequent screening than HIV-negative 
women, but that the issue of beginning screening at a younger age in HIV-positive 
women is unclear and requires study.4 The Centers for Disease Control and 
Prevention (CDC) recommends that in developed countries, HIV positive women be 
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screened for SILs more frequently than HIV negative women, having two cytological 
assessments within the first year after HIV diagnosis and annually thereafter, with 
referral for colposcopy for any smear showing an ASCUS or more severe lesion.92 
The WHO recommends that screening criteria for women with known HIV infection 
should be developed at the national level with these issues in mind.5 Cytology 
screening is equally effective in HIV-positive and HIV-negative women.  
 
If South Africa were to adopt such policies given the high HIV prevalence, the 
resultant burden on the health services would need to be considered, and intense 
preparation would be obligatory in order to cope, given the challenges with the 
current strategy. While the practice of conducting more intensive cervical screening 
for HIV positive women may be justified based on current literature, this should be 
complementary and not at the expense of the routine screening programme. The main 
objective of the cervical screening programme, even in a setting of high HIV 
prevalence, remains high coverage. While the practice of cervical screening is explicit 
in the policies of the HIV and AIDS directorate at provincial level, there are no 
concrete guidelines as to the frequency and timing of Pap smears in either the national 
cervical screening guidelines, or the National Strategic Plan related to HIV/AIDS 
care. There is some evidence that now makes it imperative to clarify issues related to 
cervical screening in HIV positive women in the national guidelines. 
 
4.1.4 Abnormal smears in young women 
In this study, the analysis of abnormal smears recorded in the district, showed that low 
grade lesions were more commonly found than high grade lesions, especially in 
younger women; and the proportion of HSIL and cancers increased in older women. 
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This is consistent with current understanding of the natural history of the disease of a 
clear relationship between age and LSIL, with younger women having a high rate of 
LSIL which decreased with increasing age.17 A similar but inverse relationship 
between age and invasive cancer is described with the rate being low in young women 
and increasing with increasing age.  Research in South Africa showed that the 
prevalence of precursor SILs was highest in women in their late thirties.93 The 
proportion of abnormal smears decreases with age, but abnormalities among older 
women have a much greater chance of leading to true malignancy.94   
 
Findings of this study reveal that 11.7% of the total smears done in all age groups in 
2008 were abnormal (including low grade and high grade lesions). This exceeds 
findings on smear abnormality in other studies, even in developing countries. For 
example, in a Brazilian study, 5.4% of Pap smears were abnormal and this was 
attributed to inadequate previous screening.80 In countries where the female 
population is screened appropriately, it has been estimated that less than 1% of Pap 
smears should harbour a cytological abnormality.58 The high rates of Pap smear 
abnormality detected in this study, raises the question of health system capacity for 
follow-up and referral and treatment facilities. If South Africa were to achieve 
screening targets, would the country cope with the resultant demand for colposcopic 
treatment services? 
 
In the evaluation of referral in sampled clinics, 21% of women with high grade 
lesions that required referral for colposcopy were younger than 30 years. The 
screening data also revealed that 4.4% of the total Pap smears done in women less 
than 30 years, revealed HSILs and cancers.  This is higher than studies in developed 
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countries which show that high grade cytological abnormalities are diagnosed in 
about 1.4% of young women screened, although this was for women under the age of 
25.94 In a population-based South African study of prevalence of cervical 
abnormalities in the 1990s, 1.5% of women less than 30 years were found to have 
HSIL and invasive cancer.17 The WHO guidelines however state that in a previously 
unscreened population of women aged between 25 and 65 years, 1 – 4% of HSIL are 
likely.5 
 
Even though this study was not population-based and relied on healthy women 
presenting at health facilities for Pap smears, and may have included large numbers of 
HIV positive women receiving pre-treatment screening, these results suggest that 
there may be an increased risk of high grade cervical intraepithelial lesions in young 
South African women.  One may infer that this is due to the high prevalence of HIV, 
especially in females in the age group 15 – 24 years, as cervical dysplasia is 
recognised as an HIV-related condition. However, this may also be ascribed to the 
sexual behaviour and practices of South African men and women, including young 
age at sexual debut, which results in high prevalence of HPV infection in young South 
African women and younger ages at which pre-cancerous lesions develop. 
 
While the WHO and IARC do recommend commencing cervical screening at 25 years 
of age where resources permit, they also suggest a rational approach to policy setting, 
with the initial focus on high coverage in high risk age groups, then expanding to 
younger groups and more frequent screening.4,5 In light of this, the debate in South 
Africa should still revolve around improving coverage with the current policy, before 
changing the age limits for initiating cervical screening. There is evidence to suggest 
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that while maintaining the current guidelines for cervical screening of the general 
population, there needs to be clear policy for screening HIV positive women at 
younger ages, with higher frequency. 
 
4.1.5 Pap smear adequacy 
In this study, we found below acceptable smear adequacy in six out of fourteen clinics 
sampled. Pap smear inadequacy was also demonstrated to be poor in other studies set 
in South Africa.13,51 In one study, more than 40% of smears taken in a district of the 
Western Cape were not satisfactory, and in many of the smears endocervical cells 
were absent.13 This was as a result of poor technique in performing the smear, where 
the endocervical junction was not sampled. 
 
Poor quality Pap smears reduce the cost-effectiveness of cytological cervical 
screening, as it necessitates repeated smears being performed. Also, smears taken 
without endocervical elements reduce the chance of detecting cervical atypia because 
the squamocolumnar junction is not sampled.95 In various studies, a large proportion 
of women who developed cervical carcinoma had had smears four to five years prior 
to diagnosis that were correctly interpreted as normal, but lacked endocervical 
elements.96,97 This suggests that the cancer might have been detected earlier had the 
smears contained endocervical elements. These studies found that Pap smears with no 
endocervical elements present had a high percentage of false-negative results. 
 
It was not determined in this study, whether there was a quality assurance system in 
place for routine monitoring of smear adequacy rates. While each Pap smear result 
received by the clinic has a comment on smear adequacy, clinic managers do not 
  
73 
routinely receive regular reports on the smear adequacy for the facility. The NHLS are 
not able to easily compile a summary of adequacy rates for all clinics due to the 
challenges associated with the cytology reporting format. The coding system for Pap 
smear results is based on multiple lines of text entry and the electronic database is not 
coded uniformly for adequacy. If the laboratory does not communicate this 
information routinely to the district, sub-district and facility managers, it is unlikely 
that the issue of smear quality is regularly addressed. However, facility managers may 
be proactive and regularly monitor smear adequacy for their staff to address any need 
for re-training on technique. 
 
According to the National Guidelines, if the smear adequacy rate for a facility falls 
below 70%, immediate action is required in the form of re-training and refresher 
courses for facility staff. It is assumed that this would be the responsibility of the 
NHLS to report, and programme and sub-district managers to act on. These systems 
are not currently in place in the Johannesburg Metro District, but a formal procedure 
is necessary to address this. 
 
Limited adequacy is almost completely due to poor sampling. This is primarily 
attributed to inadequate training of nurses performing smears, which can easily be 
addressed through education in sampling technique.13 High quality of Pap smears is 
especially important in low-resource settings, where women may undergo screening 
only once or twice in their lifetime.4 
 
 
 
  
74 
4.1.6 Loss to follow up  
An important finding in this study was the high proportion of women who have had a 
Pap smear who are lost to follow-up through the referral process. In the present study, 
the Johannesburg Metro District performed poorly on system effectiveness and 
performance measures, as the notification rate was 57%, referral appointment rate was 
38% and the appointment compliance rate was 28%.  This means that out of 557 
women with high grade lesions and cancers, only 318 received results and referral, 
211 made appointments at colposcopy units, and only 155 attended their 
appointments. There was a consistent finding of poor system effectiveness and 
performance across most clinics in the study, irrespective of health authority or sub-
district. The reasons for women not receiving their results, not making appointments 
at colposcopy clinics, or not attending colposcopy appointments, would be valuable to 
know, but were beyond the scope of this study to determine. 
 
A high level of attendance for screening is necessary but not sufficient to ensure a 
successful cervical cancer screening programme. Screened women with abnormal 
tests must also receive appropriate treatment. Rates of colposcopy attendance vary 
enormously across settings and populations. A recent systematic review described a 
10% to 40% rate of nonadherence.56 In low resource settings, levels of loss to follow-
up in cervical cancer screening programmes were as high as 70%,36  while one study 
in Peru found 77% of women with positive cytology did not have diagnostic 
investigations and treatment as required.98 In low-income minority women in a 
developed country, on any single clinic day, an average of 39% of appointments were 
no-shows.65 In South Africa, a study in the 1980s showed that 70% of women with 
abnormal smears did not attend colposcopy,53 whereas a more recent study estimated 
  
75 
colposcopy non-adherence as 50%.8 However, a South African study recorded a 10% 
non-adherence rate post screening, albeit in a research setting, with substantial focus 
placed on collecting contact details and tracing defaulters.99 
 
Non-adherence to referral is consistently cited as a significant problem in cytological 
screening programmes, and is thought to drive down the effectiveness of screening 
programmes regardless of which screening modality is used.36 Loss to follow-up has 
also been implicated as a contributing factor to adverse outcomes in retrospective 
analyses of advanced cervical disease.56   
 
Loss to follow-up in the cytological screening programme is cited as a reason to 
suggest using other modalities for screening, viz. VIA and DNA HPV testing. “See 
and treat” methods may be good alternatives because they obviate the need for 
multiple facility visits, but these strategies also have their disadvantages and are not 
recommended for routine implementation in resource-poor settings at this point.5 
Some believe that South Africa does have the infrastructure and resources to deliver a 
cytological screening programme effectively while others attributed challenges with 
cytological screening to poor programmatic quality and lack of management skills, 
rather than to technological limitations of the Pap smear test.42,49,66,76 It is said that the 
recent intense focus on other screening methods is undermining improvements to the 
current cytologic strategy. It is not necessary to debate the technology to be used, but 
rather to act through a systems approach focused on programmatic quality, and work 
to improve the current programme.49 
 
  
76 
The WHO recommends that to ensure that women with an abnormal screening test 
can be reached for follow-up, the woman’s contact details should be noted at the time 
of screening and she should be counselled on the importance of coming back for 
results and follow-up care.5 In addition, the clinic should keep a directory of all 
women with abnormal test results, indicating whether they have received the results 
and been followed up, and designate someone to ensure that follow-up is done. For 
women who do not return for follow-up, providers can send a letter by mail, telephone 
women at home or at work, or ask CHWs to contact women directly at home. 
 
Despite the importance of assuring good levels of compliance with follow-up, most 
interventions for improving the cervical screening programme have focused on 
increasing attendance in screening programmes. For example, in a Cochrane Review 
of strategies to improve cervical cancer screening attendance, only three of the 
selected 35 studies were about compliance with follow-up after screening.100  
 
4.1.7 Factors associated with colposcopy attendance 
The health service factors associated with colposcopy attendance in this study 
included the health authority, and hospital women were referred to. Women referred 
from NGO-run clinics, and those from sub-districts E and F who were referred 
exclusively to CMJAH and EH, were less likely to attend colposcopy appointments 
than those from other health authorities and sub-districts. With regards to the NGO-
run clinics, the concern is that being outside the scope of government authority, 
referral processes may be not as well-defined as they are from provincial and local 
government clinics.  Practices at the CMJAH and EH may explain why women were 
less likely to attend colposcopy. Perhaps it is related to the fact that women make their 
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own appointments at these hospitals, compared to CHBH, where appointments are 
routinely made for women by the referring clinic staff. Thus at CHBH, women were 
found to be more likely to attend the appointments, even though they had a longer 
waiting time for appointments.  
 
The literature cites a number of reasons for non-adherence to colposcopy 
appointments, including patient and health system factors.  Some patient factors that 
negatively influenced care-seeking behaviour in this respect include lack of 
understanding of the purpose of colposcopy, fear and emotional consequences of 
abnormal Pap smears, forgetting appointments, the severity of disease and a woman’s 
perception of risk.56,65 Younger age, minority ethnicity, lower education level, and 
lower grade abnormalities on Pap smears tend to be associated with decreased 
adherence to referral advice and compliance to treatment.56   
 
Health system barriers for adherence include distance, availability and access to the 
referral centre.98,101 A lack of understanding of the steps in the referral process, as 
well as poor rapport or communication with the provider results in many women 
failing to attend for results or further treatment.65,102  
 
This study did not set out to determine clients’ reasons for not attending 
appointments, but age and HIV were evaluated as possible factors associated with 
colposcopy attendance.  There was no association between clients’ age and attendance 
of colposcopy appointment. A similar finding was reported in a Western Cape study 
where adherence to referral recommendations did not differ with age.13  
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In women who had high grade lesions, those who were HIV positive were 2.4 times 
more likely to attend appointments than those in whom HIV status was unknown.  An 
assumption can be made that further treatment for these women was dependent on 
them completing ART pre-screening protocols. It seems likely that these were women 
who were being referred from ART-rollout sites, so they were in essence “in the 
system” and were more likely to comply with referral processes. These women were 
also most likely recipients of intensive counselling as a result of their HIV diagnosis 
and possible commencement of ART. The health messages they were likely to receive 
would positively influence their health-seeking behaviours. Another study conversely 
found higher rate of loss to follow-up in HIV positive women.103 
 
Provider behaviour is known to have an effect on referral of women with high grade 
lesions.13,51 Health services in this study did not have processes in place for call and 
recall of clients after Pap smears were done, and this may in part account for the high 
loss to follow-up observed. In this study, not all women had contact details recorded 
in the Pap registers; however, women whose contact telephone numbers were 
recorded were more likely to attend appointments, although this association was not 
significant in the multivariate analysis. If a woman did not attend her appointment to 
receive the Pap smear result, the clinic would have no way of contacting her, and 
especially of referring her to colposcopy in the event of an abnormality requiring 
further investigation and management. Of more concern, the colposcopy appointment 
registers do not reflect any contact details- so if a woman did have a Pap smear at her 
local clinic; did return and was given her result; did make an appointment for 
colposcopy; but failed to attend that appointment; she was essentially lost to the 
system. Furthermore, the colposcopy clinic at each hospital does not call clients who 
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failed to attend an appointment to reschedule. This reflects a serious weakness in the 
cervical screening programme, as high loss to follow-up reduces the cost-
effectiveness of this screening method and will hamper efforts to decrease disease 
incidence and mortality. 
 
In many developed countries, personal health information systems enable easy 
identification of women who fail to attend follow-up appointments.  The lack of these 
systems in developing country settings such as Brazil, have made it very difficult to 
implement call and recall systems.42 A study in Peru suggests a system to record 
details of screening dates, results and treatments to be kept by the women and taken 
from visit to visit, as a means of improving screening and referral.98 In South Africa, 
it has been suggested that a woman’s health card could be used as a continuous record 
of care, which would provide a link between screening information and colposcopy 
data.51 
 
Interventions to improve adherence employ a broad range of methods focusing on 
systemic/structural and behavioural contributors, and have achieved varying 
success.104 A systems intervention in the Netherlands appeared to be effective in 
improving client adherence to follow-up recommendations. The quality improvement 
interventions included utilising computerised patient information recording system, 
delegation of clinical tasks to practice assistants, provision of outreach support to 
trace defaulters and issuing of reminder letters.105 
 
Among the most effective behavioural strategies to improve referral adherence are 
personalised reminders to patients by healthcare workers.98 Appointment reminder 
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systems are being employed in developing country settings such as Zambia, involving 
text messages to remind patients of appointments, telephone calls to re-schedule 
missed appointments, and if these fail, lay health worker follow-up at the patient's 
home.36 
 
The opportunities for innovation in use of mobile technology in delivering 
information, mass communication and service delivery are enormous. Cellular phones 
should be systematically used for tracing patients in the cervical screening programme 
who require referral, especially in a country like South Africa with high cellular 
phone penetration.73,79  
 
The use of CHWs should also be explored, in reaching areas with poorer access to 
communication lines. Local agents have the advantages of shared culture, class and 
language which can promote understanding, even among women with low 
educational background.97 In many developing countries, successful follow-up of 
women with abnormal screening tests has been achieved by using dedicated personnel 
to re-contact these women.  Improvements in follow-up of between 89% and 100% 
have been documented from studies in Cameroon, China, Costa Rica, South Africa, 
Venezuela Vietnam and Zimbabwe.49 Use of CHWs was also found to be cost-
effective in studies in the Western Cape, South Africa.36 
 
Another factor related to poor attendance of appointments in this study, is the long lag 
time between Pap smear and colposcopy attendance. In a study in the Western Cape, 
adherence to recommendations for a follow-up Pap smear were significantly lower for 
women who were asked to return at 12 months compared to those who had to return 
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for follow-up at 6 months.13 In this study, it was found that clients had to wait as long 
as 15 months for attending a colposcopy appointment. In the Gauteng Province and 
nationally, even for other non-emergency health services provided at higher levels of 
care, e.g. surgery for cataracts and tonsillectomies, there are significant waiting 
times.106 This is due to the huge catchment populations causing large patient loads at 
public hospitals, and also the lack of services being available at district level.   
 
It is not known from this study why there were long lag times between Pap smears 
and colposcopy attendance. One reason could be the limited availability of 
colposcopy services at referral hospitals in South Africa.9 Insufficient numbers of 
colposcopy clinics to serve the population size and a shortage of human resources 
result in an inadequate supply of colposcopy services. Colposcopy services are only 
provided at three facilities within the JMD, a district that conducted over 60,000 Pap 
smears in 2007/8.60  Each of these three colposcopy units are functioning at near-
maximal capacity, and have had to provide services to the 3 154 women with pre-
cancerous and cancerous lesions in 2008 that required colposcopy. It is possible that 
colposcopy services have not been extended within the district due to equipment and 
personnel constraints. This shortfall in colposcopy services requires primary attention 
to improve programme effectiveness. An article on the estimated human resource 
requirements for introducing a cervical cancer screening programme in South Africa, 
suggested that every regional hospital in the country would be required to create and 
run a weekly colposcopy clinic in order to achieve coverage goals.107 A recent 
strategy in Scotland to establish a colposcopy service at the family planning centre 
provided more rapid access to colposcopy, and avoided long waiting times that 
patients normally endured at the specialist hospital.108 The authors argue that as long 
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as there are close working links with the hospital centre, large referring clinics can 
establish a successful colposcopy service.  
 
From the findings of this study, various health system-related factors have been 
identified that may be responsible for poor attendance of colposcopy services by 
women with high grade lesions.  This study suggests that the poor system 
effectiveness and performance relate to practices and processes at the clinics and the 
referral hospitals, and include issues of record keeping, procedures for making 
colposcopy appointments, and capacity at the referral colposcopy services.  
 
Without efficient diagnostic services and therapy, screening would hardly be 
justifiable.109 Screening by itself will not prevent a single case of cervical cancer. An 
effective system for follow-up and treatment of women who test positive is perhaps 
the most important component of a successful cervical cancer prevention programme. 
This would require the underlying systemic issues of staffing, training and 
infrastructure to be addressed. To provide an effective screening programme 
ultimately would necessitate a functional health system.10 
 
4.1.8 Challenges in monitoring the cervical screening programme 
While this study highlighted serious challenges in implementing the cervical 
screening programme, it also revealed constraints with available cervical screening 
data, a valuable finding in itself. There are various limitations with the data that is 
used to monitor the programme, including primary data collected on the numbers of 
screening Pap smears done (numerator) and also the assumptions used in determining 
target populations (denominator) when calculating coverage. 
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In determining the number of screening Pap smears done, this study relied on existing 
routinely collected data at the facilities. The validity, reliability and completeness of 
these registers cannot be guaranteed. It is unsure whether all staff completing monthly 
collation sheets have the correct understanding of the criteria for screening Pap 
smears, which are used to determine screening coverage. If, for instance, diagnostic 
Pap smears, those done for HIV positive women or for women outside the target age 
groups, are included in the figures reported in the DHIS, this would overestimate the 
screening coverage. Furthermore, it cannot be excluded that multiple Pap smears may 
have been done for the same individual in one year, which would overestimate 
coverage. 
 
The target population of women over 30 years of age is derived from census data. 
There are some assumptions made with regards to the reprocessing of census data for 
derivation of population estimates. Stats SA publishes national and provincial 
population estimates annually, based on the census, the most recent having been 
conducted in 2001. Projections are made for national and provincial populations, 
using various methodologies.110 A comparison shows that the projected 1996 
population figures were about 1,2 million higher than the published 1996 Census, 
while a very small difference can be found between the published 2001 Census and 
this projection on that date. The DHIS uses this data to prepare projections at district 
and sub district level through an iteration process using estimated birth, death and net 
migration data. There have been numerous problems reported with the Spectrum 
model software used by Stats SA to derive estimates of the population size.111 
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Also, the data collected by the DHIS reflects Pap smears done in all public sector 
facilities, yet the denominator (catchment population) includes all women, insured 
and uninsured. Including insured women in the denominator, who most likely have 
had Pap smears in the private sector which is not reflected in the numerator, may 
underestimate the screening coverage.  
 
It is important to address these data challenges, as effective monitoring of the cervical 
screening programme is essential to its successful implementation. 
 
 
4.2 Limitations 
The study relies on existing data collected and recorded in registers at the facilities, in 
order to identify women who have high grade lesions found on Pap smear, and then to 
trace whether they have attended colposcopy.  The data analysed in this study depends 
on the quality and consistency of these existing data and records at the facility level, 
and therefore would result in incorrect estimates of referral, adherence and other 
indicators where data may not be accurate or complete. However, every effort was 
made to utilise multiple data sources when possible to minimise this limitation.  
 
The sample of clinics was chosen to be representative of the entire district.  However, 
the results may not be generalised to other districts or provinces in the country, as the 
strength of the cervical screening programme and health institutions’ capacity to 
implement the service may differ vastly in other settings. Johannesburg Metro District 
is known to be better-served with healthcare facilities, human resources and referral 
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sites. However, the trends and system challenges highlighted here may also be 
applicable to other districts in South Africa. 
 
In using data recorded on HIV status, it is acknowledged that this information was not 
systematically collected or recorded for all patients. This kind of opportunistic data is 
therefore only used to demonstrate the differences between clinics that were screening 
only HIV positive patients versus those that were conducting general screening of the 
target age group. As far as possible, no inferences were drawn regarding HIV status 
due to the bias in collection of this data. 
 
Despite the issues related to limitations of data quality and the data sources, this study 
still presents valuable and useful information on the cervical screening programme in 
this setting, and offers an insightful account of the challenges that must be addressed 
in order to improve the programme, to see declines in rates of disease and death from 
this disease. 
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CHAPTER FIVE 
5. CONCLUSION AND RECOMMENDATIONS 
 
5.1 Conclusion 
This study demonstrated that cervical screening coverage has improved since 
inception of the programme but still falls short of what is required for achieving the 
national cervical screening programme goals. The study confirms the many barriers to 
delivering an effective cervical screening programme that exist in the Johannesburg 
Metro District, Gauteng Province. 
 
Key challenges demonstrated by this study include low screening coverage, continued 
screening targeted to young women outside the target age groups, poor Pap smear 
adequacy, and inadequate referral of women with high grade lesions and cancers for 
diagnosis and treatment. Some of the reasons for the poor system effectiveness and 
performance relate to provider practices, record keeping, and referral processes. 
 
Addressing these challenges is important to improve the effectiveness of the 
programme. Only by reorganising and improving implementation of the current 
programme, will the impact on cervical cancer incidence and mortality be seen.   
 
If South Africa is to reorganise the ineffective current national cervical screening 
programme, it would require strong political commitment, translated to well-
implemented services, establishing a trained and motivated health workforce, 
improving the organisation of services, and strengthening its health system.43  
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5.2 Recommendations 
The WHO recommends that in developing countries, existing ineffective cervical 
screening programmes should be urgently reorganised and monitored.7 It is further 
said that screening programmes in developing countries can achieve success through 
strong programme managers who prioritise quality.112 To decrease incidence and 
mortality rates from cervical cancer, South Africa must improve implementation of 
the national cytological cervical screening programme. This requires process 
improvements in all areas, especially increasing screening coverage of target age-
groups and effective referral and treatment of women with high grade lesions. It may 
also require a detailed look at practices with regard to screening in younger age 
groups and HIV positive women.  
 
 
1. Improve cervical screening coverage 
A cervical screening programme must achieve high screening coverage over 80% to 
impact on cervical cancer outcomes.5 The JMD should look into reasons for low 
coverage and then focus its efforts on strategies known to improve coverage: 
 
1.1. Raise community awareness 
This may involve a variety of strategies, including mass awareness campaigns using 
the media, e.g. billboards, newspaper articles, advertisements, radio-spots, photo-
comics, and features in health educational programmes on television (Soul City). To 
be effective, these interventions require high coverage.   
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1.2. Improve client recruitment 
This involves training of healthcare workers to “accept” the policy. Staff would be 
encouraged to opportunistically recruit women in the target age group who may be 
attending the clinic for other reasons, ensuring that there are no missed opportunities 
and that all women in the target age group who have contact with the health system 
are reached.  Women should not be recruited only from the family planning clinic or 
ART programme as is often done, as this will not allow for screening in women 
beyond the reproductive age. Also, Pap smears should be done on the same day that 
the woman is recruited at the clinic. Peer educators and of nurses should be trained in 
order to improve awareness and increase referral of HIV positive women for 
screening tests.113  
 
1.3. Set monthly targets 
Clinics that set monthly targets were generally found to maintain higher screening 
coverage.  Instead of using a fixed number per clinic, these targets should be decided 
by a formula based on estimates of the clinic catchment population, or facility 
utilisation. One local study found that a quota system in one health district of twenty 
smears per month per health facility, actually limited the number of smears that 
should have been done in that population.75 
 
1.4. Hold screening “drives” 
The GDoH should consider as a strategy, implementing the innovative example set by 
one clinic that organised a one-day cervical screening drive. It may be more cost-
effective to concentrate resources on raising community awareness for a screening 
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campaign to be held on a specified day. However, there is no evidence that such 
“drives” would lead to sustained increases in coverage. 
 
1.5. Improve smear adequacy 
As per the national guidelines, the province should develop a protocol for monitoring 
smear adequacy across all facilities. The NHLS should be engaged, and requested to 
provide programme and sub-district managers with routine monthly reports of facility 
adequacy data. This information should be regularly fed-back to the facilities, and re-
training and refresher courses held for all clinics that fall below the 70% adequacy 
mark. 
 
 
2. Ensure referral and treatment of women with high grade lesions 
Ensuring treatment of abnormal Pap smears is a challenge, but unless referral and 
access to colposcopy services is improved, increasing screening coverage will not 
have an impact on decreasing cervical cancer rates. Some health service issues that 
should be addressed include: 
 
2.1. Improve referral system 
It is important to address the failure of the referral system with regards to cervical 
screening. Providers should consistently refer women for colposcopy when indicated, 
and this can be improved through training and continuous reinforcement of the 
guidelines. As some clinics, hospitals, sub districts and health authorities were 
demonstrated in this study to perform better, it would be important to adopt best 
practices and ensure standardisation of referral practices throughout the district. 
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2.2. Improve data recording and management 
Ensure that contact details for all women at screening and colposcopy services are 
recorded, and that staff have access to communication systems to contact women for 
re-call. By recording contact details in Pap register and colposcopy appointment 
registers, and employing a woman’s health card, we would be better able to track 
women through the referral system and recall them if they have failed to attend 
colposcopy appointments.   
 
2.3. Improve client adherence 
Strategies that could be explored include increasing patient awareness and 
counselling, physical or economic barrier reduction, and health service interventions 
to trace women who default. The introduction of various reminder systems using 
motivational pamphlets, explanatory informational brochures, telephone (SMS) 
reminders, and the use of CHWs have proven to be effective in other settings.56 
Increasing understanding about screening is the first step as women who do not 
understand why they are being screened are less likely to return for results and 
possible further treatment.114  
 
2.4. Increase availability of colposcopy services 
This study suggests a need for more colposcopy services in the district. It is unlikely 
that the facilities that currently have colposcopy units will be able to increase their 
capacity, but this should be explored. The province should urgently consider 
extending the colposcopy services to other hospitals, e.g. South Rand Hospital, and 
possibly to community health centres (CHCs). This would decrease waiting times and 
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possibly increase attendance of colposcopy appointments. If there are more referral 
centres available, the ideal would be to strive for a same-day service, to avoid further 
losses to follow-up of women who make, but do not attend colposcopy appointments. 
 
 
3. National review of current cervical screening practices 
It is necessary to achieve uniformity and standardisation of practice with regard to age 
at which screening is initiated and screening in HIV positive women. 
 
3.1. Clarify appropriate age to initiate screening 
Many providers do Pap smears on women under 30 years as they do not understand or 
agree with the current policy.51 In light of conflicting opinion and practices currently, 
it would be prudent to hold expert consensus meetings, which would inform and 
clarify national policy and set uniform screening practices. 
 
3.2. Formalise policy on cervical screening in HIV positive women 
The practice of screening only HIV positive women that has been observed at many 
health facilities must be addressed.  The national cervical screening policy of 2000 
was formulated before the link between HIV and cervical cancer was firmly 
established, and does not address the issue of cervical screening in HIV positive 
women.91 The current cervical screening policy should be expanded to specifically 
include guidelines on initiation and frequency of screening in HIV positive women. 
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5.3 Further Research Areas 
 
1. The reasons for the low screening coverage should be investigated. A study 
should be done on the knowledge, attitudes and practices of women in JMD 
regarding the need for cervical screening. A similar study of staff at the clinics 
providing Pap smears would reveal any reasons to explain poor client 
recruitment. This would enable programme managers to introduce appropriate 
interventions aimed at improving the uptake of cervical screening services. 
 
2. In light of some of the differences found in practice between clinics run by 
different authorities, a study looking at management, processes and resources at 
the different settings would identify whether these contribute to variations in 
performance and outcomes between clinics run by provincial, local government 
and NGO authorities. 
 
3. A study is also warranted to investigate the current status of cervical screening 
for HIV positive women in the public sector, looking at the age at which 
screening is initiated and the frequency of screening in this group. 
 
4. It would be important to conduct studies to determine the HSIL treatment rate. 
This study has only focused on the effectiveness of referral of women with 
abnormal Pap smears to colposcopy services. It has not, however, explored the 
subsequent management of these women.  
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5. A study should be conducted to determine women’s reasons for non-adherence to 
colposcopy clinic appointments. 
 
6. More updated publications on national cancer statistics are vital in order to assess 
the impact of the cervical screening programme on disease trends. 
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1             
2             
3             
4             
5             
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7             
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